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ABSTRACT OF DISSERTATION

THE DISORDERED REGULATION OF CALCINEURIN: HOW CALMODULININDUCED REGULATORY DOMAIN STRUCTURAL CHANGES LEAD TO THE
ACTIVATION OF CALCINEURIN
Calcineurin (CaN) is a highly regulated Ser/Thr protein phosphatase that plays
critical roles in learning and memory, cardiac development and function, and
immune system activation. Alterations in CaN regulation contribute to multiple
disease states such as Down syndrome, cardiac hypertrophy, Alzheimer’s
disease, and autoimmune disease. In addition, CaN is the target of the
immunosuppressant drugs FK506 and cyclosporin A. Despite its importance,
CaN regulation is not well understood on a molecular level. Full CaN activation
requires binding of calcium-loaded calmodulin (CaM), however little is known
about how CaM binding releases CaN’s autoinhibitory domain from the active
site. Previous work has demonstrated that the regulatory domain of CaN (RD) is
disordered. The binding of CaM to CaN results in RD folding. Folding of the RD in
turn causes the autoinhibitory domain (AID) located C-terminal to the RD to be
ejected from CaN’s active site. This binding-induced disorder-to-order transition
is responsible for the activation of CaN by CaM. In this work, we explore the
nature of the disorder in the RD and its transition to an ordered state,
demonstrating that the RD exists in a compact disordered state that undergoes
further compaction upon CaM binding. We also demonstrate that a single CaM
molecule is responsible for binding to and activating CaN. Finally, we determine
that the CaM binding to CaN induces an amphipathic helix (the distal helix) Cterminal to the CaM binding region. The distal helix undergoes a hairpin-like
chain reversal in order to interact with the surface of CaM, resulting in the
removal of the AID from CaN’s active site. We employ site-directed mutagenesis,
size-exclusion chromatography, protein crystallography, circular dichroism
spectroscopy, fluorescence anisotropy and correlation spectroscopy, and
phosphatase activity assays to investigate the ordering of CaN’s regulatory
domain, the stoichiometry of CaN:CaM binding, and the impact of the distal helix
on CaM activation of CaN.
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Chapter 1: Background and Introduction
Calcineurin: an overview
Calcineurin (CaN) is a heterodimeric calcium/calmodulin activated serine/threonine
protein phosphatase. It was originally identified by three separate groups: Wang and
Desai,1 Watterson and Vanaman,2 and Klee and Krinks.3 Each group identified CaN as an
inhibitor of the calmodulin (CaM) activated cyclic 3’, 5’-nucleotide phosphodiesterase.
The reason for CaN’s apparent inhibition of the cyclic 3’, 5’-nucleotide
phosphodiesterase is that CaN binds to and thereby depletes CaM, preventing activation
of cyclic 3’, 5’-nucleotide phosphodiesterase by CaM.
It was later learned that CaN is a calmodulin activated protein phosphatase and has a
multitude of targets and interacting proteins. CaN is well conserved among eukaryotes. In
lower eukaryotes, such as S. cerevisiae, CaN functions in pathways for growth, motility,
stress response, and calcium homeostasis, among others.4 In humans CaN has many
targets across most tissue types, but CaN’s most well-known target is the nuclear factor of
activated T-cells (NFAT) family of transcription factors. It is CaN’s activation of NFATs
that makes CaN the target of the immunosuppressant drugs that are given to patients who
have had organ or tissue transplants to avoid rejection of the transplant.4,5
Besides immune system involvement, CaN plays a role in cardiac, vasculature, nervous
system, and musculature development. CaN signaling is also necessary for learning and
memory, skeletal muscle growth, and immune system activation.4 Because of its roles in
these varied signaling systems inappropriate CaN regulation has been implicated in a
number of pathological states including Alzheimer’s disease,6 Down syndrome,7 and
cardiac hypertrophy.8,9
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Calcineurin Signaling
Nuclear factor of activated T-cells (NFAT)
The nuclear factor of activated T-cells (NFAT) family of transcription factors is composed
of five members, NFAT1-5 (or NFATc1-c5), and CaN regulates NFATs 1-4.10 The NFATs
are transcription factors that can activate a variety of gene programs depending on the
tissue type, NFAT type, number and location of NFAT phosphorylations, and binding
partner that the NFAT associates with when in the nucleus.11-13 Under resting cell
conditions NFAT is maintained inactive in the cytosol by multiple phosphorylations that
prevent use of the NFAT nuclear localization signal (NLS).14,15 The number and location
of the phosphorylations also determine NFAT’s affinity for DNA, but the mechanism by
which phosphorylations determine DNA affinity and hide the NLS are unknown.14-18
The NFATs interact with CaN via a conserved ~300 amino acid sequence that is encoded
by a single exon.11,19 This CaN interacting domain begins ~100 residues from the Nterminus and is N-terminal to the DNA binding region (Figure 1.1). The CaN interacting
domain includes two serine rich gatekeeper regions (SRRs) and three SPxx motifs, all of
which can have multiple phosphorylations. Additionally, this region contains two CaN
interacting motifs: a PxIxIT motif and a LxVP motif.11 The PxIxIT forms a β-strand that
lines up with and completes a β-sheet on the outer edge of CaN’s catalytic domain.20 The
LxVP motif interacts with CaN at the interface of the two CaN subunits.21 These two
docking sites are on the same face of CaN as the active site but opposite sides of the
catalytic domain. NFAT’s phosphorylations are in the region between these two motifs,
thus the CaN binding motifs act as anchors to bring the phosphorylation sites in
proximity to CaN’s active site (Figure 1.2). Many other CaN targets employ one or both
of these binding motifs to dock with CaN. The affinity of substrates for CaN seems to be
determined by the variable amino acids in the PxIxIT or LxVP motif that the substrate
uses.22

It is thought that these docking sites are what determine CaN’s substrate

specificity.21
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When intracellular calcium levels rise, CaN is activated by calcium/calmodulin and can
then dephosphorylate NFAT. CaN dephosphorylation of sites in NFAT’s CaN interacting
domain exposes the NFAT NLS which is located in the same domain. Once NFAT’s NLS
is revealed it is relocated from the cytoplasm to the nucleus.14-18 In the nucleus NFATs
can bind DNA in monomer form, as a homodimer, or as a heterodimer with a number of
different transcription factor partners: AP-1 (Fos-Jun heterodimer), GATA4, and MEF2 to
name a few.5,23-25 The dimer partner helps to determine which genes are affected by
NFAT and allows for integration of multiple signaling pathways.
Once in the nucleus and partnered with the appropriate partner, NFAT acts as a
transcription factor or repressor to up-regulate or down-regulate entire gene programs.
NFAT acts on distal promotors, and its consensus sequence is (A/T)GGAAA.5 When
NFAT is paired with other transcription factors, the dimer binds to composite sites with
both the NFAT consensus sequence and the sequence for the NFAT partner.11 The various
NFATs often have overlapping functions, and deletion of two or more NFAT types are
usually necessary to observe an altered phenotype.26
Calcineurin/NFAT signaling is necessary for proper fetal development and adult
homeostasis in many calcium sensitive tissues including the heart, vasculature, nervous
system, immune system, skeletal muscles, bone, pancreatic β-cells, and kidneys.13 During
fetal heart development, CaN dephosphorylation of NFAT3 and NFAT4 leads to an
increase in cardiac contractile proteins and oxidative metabolic proteins; signaling
through NFAT1 is necessary for valve development; and signaling through NFAT2 is
involved in angiogenic remodeling.9,24,27 CaN/NFAT signaling was discovered via its role
in the immune system and is very well studied in this system.28,29 NFATs are necessary
for differentiation of T-cells, and NFAT1 and NFAT2 are required for cytokine production
in stimulated T-cells.30 In skeletal muscles, CaN/NFAT signaling, under conditions of
chronic muscle activity, induces expression of myosin heavy chain 1 (MyHC1). MyHC1
expression is necessary for muscle fiber switching from fast-twitch to slow-twitch fibers.
11

NFAT2 activity is essential for osteoclast progenitor differentiation in bones.31,32 In
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pancreatic β-cells the insulin gene has a known NFAT promotor, and β-cell specific
depletion of CaN in mice results in age-dependent diabetes.33-35 CaN signaling through
NFAT is necessary for renal development at the earliest stages and plays a role in salt and
water homeostasis.36-38
The above examples are just a fraction of the signaling pathways under the influence of
CaN/NFAT signaling. Additionally, CaN has a multitude of targets besides NFAT in these
and other systems. In the following section I will discuss CaN’s well known, if not fully
understood, role in long-term depression at excitatory synapses. This example is given in
order to explore important non-NFAT CaN signaling.
Long-Term Depression at Excitatory Synapses
Long-term potentiation (LTP) and long-term depression (LTD) are mechanisms used at
the post-synaptic neurons of excitatory synapses to sensitize or desensitize, respectively,
the receiving neuron to excitation stimuli. LTP strengthens the connection between
neurons while LTD weakens it. These processes are important in learning and memory.
LTP and LTD are very complex and the mechanisms for LTP and LTD induction can be
different depending on the type and architecture of the synapse. What follows is a brief
overview of the role CaN plays in LTD.39
The NMDA receptor (NMDAR), calcium-permeable AMPA receptor (AMPAR), and
calmodulin activated kinase II (CaMKII) are important in LTP.39-43 NMDAR and AMPAR
are both glutamate receptor cation channels located on post-synaptic neurons. NMDAR is
also a voltage-gated channel. When glutamate binds the receptors AMPARs are opened,
allowing the influx of cations, including calcium. In addition to glutamate binding,
NMDAR requires depolarization of the post-synaptic neuron to open. Depolarization
releases a magnesium ion in NMDAR pores, allowing the influx of cations.39-41 LTP can
occur if the excitatory stimuli is strong enough causing both receptors to open, and the
influx of calcium through NMDARs allows the activation of CaMKII. CaMKII then
phosphorylates AMPARs, making them more sensitive to excitatory stimuli, thereby
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reinforcing the stimulus. CaMKII also assists in increasing the number of AMPARs at the
membrane.39,41,42
LTD occurs when a persistent, weak excitatory stimulus is applied to the post-synaptic
neuron. This opens AMPARs, allowing a cation influx that is not strong enough to
depolarize the cell. Lack of depolarization maintains NMDARs in their closed state so
that CaMKII is inactive.39 CaN is anchored to the dendritic membrane by the scaffolding
protein AKAP79.12 When AMPARs allow the influx of calcium, CaN is activated and
dephosphorylates AMPARs, desensitizing them to excitatory stimuli.12,43 CaN activity
may supersede CaMKII activity under these circumstances because, while both are
calcium/calmodulin activated, CaN has a much higher affinity for CaM than CaMKII
does (KD ~1pM and ~300nM, respectively) and because CaMKII is associated with
NMDARs when inactive, not AMPARs .44,45 While, as mentioned, LTP and LTD are
much more complex than the brief explanation given, CaN’s role in LTD is its
dephosphorylation of AMPARs, and this dephosphorylation is crucial for LTD.
CaN Signaling in Human Health
We have discussed CaN’s role in the development and maintenance of several human
organ/tissue systems, so we can see how altered CaN signaling can lead to a host of
different pathological states. CaN mis-regulation has been implicated in cardiac
hypertrophy,8,9 Alzheimer’s disease,6 and Down syndrome.7
When CaN/NFAT signaling is chronically activated in adults, the fetal gene program is
reactivated, and it leads to cardiac hypertrophy which is a leading predictor of congestive
heart failure. In fact, constitutively activated CaN, NFAT3, or NFAT4 can induce massive
cardiac hypertrophy in mice, including increased myocyte size, an increase in collagen
and fibrous tissue, and often congestive heart failure or sudden death.9,24,27
CaN has been shown to dephosphorylate Tau protein. The hyperphosphorylated form of
Tau can form neurofibrillary tangles, a hallmark of Alzheimer’s disease in human brain.
CaN activity is shown to be decreased in the brains of Alzheimer’s disease patients.
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Decreased CaN activity could lead to hyperphosphorylated Tau, and, thereby,
neurofibrillary tangles.6,46
Regulator of calcineurin 1 (RCAN1) is an endogenous regulator of CaN.47 The gene for
RCAN1 is found in the Down syndrome critical region (DSCR) of chromosome 21, and
is overexpressed in individuals with Down syndrome.

48

Overexpressed RCAN1

chronically inhibits CaN. Mental retardation, muscle hypotonia, and immune deficiency
are all characteristic Down syndrome pathologies.49 It is thought that chronic CaN
inhibition by RCAN1 contributes to these pathologies.7,48 As mentioned in the previous
CaN signaling sections, CaN contributes to learning and memory, skeletal muscle
development and maintenance, and immune system activation. Additionally, Down
syndrome patients almost invariably develop early-onset Alzheimer’s disease if the
patient lives past ~35 years.7,49 It is possible that decreased CaN activity due to increased
RCAN1 levels contributes to this occurrence of Alzheimer’s disease.
Finally, CaN is the target of the immunosuppressant drugs FK506 (also known as
tacrolimus) and cyclosporin A.18,50 These drugs are necessary for patients who have had
tissue or organ transplants as they help to prevent rejection of the transplant. In cells,
FK506 binds FKBP12 (FK506 binding protein 12), and cyclosporin A binds cyclophilin.
These proteins are prolyl-isomerases. The binding of the drugs to their protein partners
allows the complex to then bind CaN, preventing NFAT binding and dephosphorylation.
51-54

Without NFAT signaling, T-cells are not activated, which allays immune system

attack on transplanted tissues.
The vast network of CaN/NFAT signaling, CaN signaling in the very important process of
LTD, and the impact of altered CaN signaling on human health demonstrates the large
scope and importance of CaN function. However, despite extensive studies concerning
CaN there is much we do not understand about the protein itself and its activation by
calcium-loaded calmodulin (CaM). In the following sections, we will explore what is
known about CaN structure and activation as well as some of the aspects of CaN
structure and activation that we do not fully understand.
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Calcineurin Structure and Activity
CaN is a heterodimer composed of a 57-61kDa A chain (CnA) and a 19kDa B chain
(CnB). CnA is composed of the catalytic domain, CnB binding helix (CnBBH),
regulatory domain (RD), autoinhibitory domain (AID), and C-terminal tail (CT) (Figure
1.3).55

At low calcium concentrations the AID resides in the catalytic site of CnA,

keeping the enzyme inactive. When calcium levels rise, calcium loaded CaM binds to the
CaM binding region (CaMBR) located in the regulatory domain of CnA. CaM binding
releases the AID from the catalytic site, activating CaN (Figure 1.4).56 CnB is a calcium
binding EF hand protein that is structurally homologous to CaM. While CnB can bind up
to four calcium ions, it is constitutively bound to CnA, regardless of calcium
concentrations.57 There are three CaN isoforms: αCaN is found primarily in neurons,
βCaN is ubiquitous, and γCaN is testes specific. The differences in regulation and activity
between isoforms is unclear.58 In this work CaN refers to αCaN.
Calcineurin A
The catalytic domain of CnA has a β-sandwich fold consisting of two central β-sheets
surrounded by a mixture of α-helices and β-sheets (Figure 1.3).51,52 This architecture is
consistent with the phosphoesterase motif common in enzymes involved in hydrolyzing
phosphoester bonds including protein phosphatase 1, protein phosphatase 2a, alkaline
phosphatase, and phosphodiesterase.59 The active site of CaN has a dinuclear metal center
consisting of Fe3+-Zn2+. The Fe3+ is coordinated by Asp90, His92, Asp118, and three
waters. The Zn2+ is coordinated by Asn150, His199, His 281, Asp118, and a water that it
shares with the Fe3+.4,52 In addition, it is thought that Arg122 and Arg254 are necessary to
help stabilize the negative charge from phosphate in the active site during catalysis.4,52 It
is believed that the catalysis proceeds via direct transfer of the phosphate moiety to a
metal activated water molecule. The metal activated water initiates a nucleophilic attack
on the phosphate group, assisted by the two histidines.4
Beyond the catalytic domain, which is the N-terminal portion of CnA, there is the
CnBBH where CnB binds. C-terminal to the CnBBH is the regulatory domain (RD). The
7

RD is a disordered stretch of CnA which houses the CaMBR and will be discussed in
more detail below. At the end of the RD is the AID which exists as a distorted helix in the
catalytic site in the CaN crystal structure.52 Beyond the AID is the C-terminal tail (CT)
which is disordered and has no known function (Figure 1.3).
Calcineurin B
CnB is a calcium binding EF hand protein that is homologous to CaM. It has an Nterminal lobe and a C-terminal lobe, each of which binds two calcium ions.57 The Cterminal lobe binds calcium with high affinity and is considered to be constitutively
calcium and calcineurin bound. The N-terminal lobe has a lower calcium affinity and
must bind calcium for CaN to have efficient phosphatase activity against peptide
substrates.56,60 CnB binds the CnBBH of CnA in an antiparallel fashion. The C-terminal
lobe binds to the N-terminal portion of the CnBBH and is adjacent to the CnA catalytic
domain while the N-terminal lobe binds to the C-terminal portion of the CnBBH.
Studies suggest that CnB plays a regulatory role in CaN function. Without calcium (in the
presence of EGTA) limited proteolysis with chymotrypsin cleaves the CnB linker and
first helix, but the CaMBR containing RD, is protected. Conversely, in the presence of
calcium, all of CnB is protected and the RD is rapidly degraded.56 This suggests that a
portion of the RD interacts with the CnBBH when the N-terminal lobe of CnB is not
calcium bound, but a conformational change occurs upon calcium binding that releases
the RD, likely so that it is available for interaction with CaM.
CnB also appears to impact substrate LxVP motif interaction with CaN’s LxVP docking
site which is critical for substrate dephosphorylation and thought to be a mode of
substrate recognition.21,61-63 The LxVP docking site is found at the CnA-CnB interface.21
Substrate only binds the LxVP site of active CaN.61-63 A truncated CnA (catalytic domain
and CnBBH only) with CnB bound shows normal Vmax levels with a peptide substrate, as
would be expected without the AID in the active site. However, the Km of this truncated
CaN is five times higher than active, native CaN. Addition of calcium (binding the Nterminal lobe of CnB) reduces the Km to native levels.64 This suggests that CnB calcium
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binding affects CaN substrate affinity, giving CnB a regulatory, not just structural, role in
the CaN heterodimer.
Calcineurin Activation
Under resting calcium conditions, CaN is maintained in an inactive state by its
autoinhibitory domain (AID) bound to CaN’s catalytic site. When calcium levels rise,
calmodulin (CaM) binds calcium and then binds to the calmodulin binding region
(CaMBR) of CaN, located in the regulatory domain (RD) (Figure 1.4).56
CaM is a 148 amino acid, 16.7kDa protein that is a major transducer of calcium signaling
in cells.65 CaM binds to and regulates ~300 cellular targets.66 CaM is composed of two
lobes connected by a flexible linker, often referred to as a dumbbell shape (Figure 1.5a).
CaM has four calcium binding sites, two in each lobe. While there are several types of
sequences that CaM binds to, calcium loaded CaM preferentially binds to basic,
amphipathic, α-helical sequences (BAA sequences).44,66,67 The CaMBR of CaN is a BAA
sequence.66,68 In some cases, as with CaN, the CaM target sequence is disordered but
prone to α-helicity, as measured by the ability of 2,2,2-Trifluorethanol (TFE) to induce
helix in the sequence.69 TFE is well known to induce α-helical structure in peptides
possessing a propensity to be helical.
Typically, when CaM binds BAA sequences, the CaM central linker helix becomes
flexible and its two CaM lobes wrap around the target to form a compact ellipsoid
(Figure 1.5b).66,67 The manner in which CaM binds CaN is still not completely
understood. Crystal structures of CaM bound to a peptide of the CaMBR of CaN done by
Ye et. al. and Majava et. al show CaM bound to CaN in a 2:2 manner with one lobe of
CaM bound to one end of a CaMBR peptide while the other lobe is bound to another
CaMBR (Figure 1.6). However, small angle x-ray scatter (SAXS) and size exclusion
chromatography (SEC) performed by Majava et al. demonstrated a 1:1 CaM:CaMBR
complex.70 Native-gel analysis and SEC on CaM:CaMBR by Ye et al. showed both a 2:2
complex and a 1:1 complex, with 1:1 being the dominate species. Also, through extensive
hydrodynamic studies, O’Donnell et al. demonstrate a 1:1 CaM:CaMBR complex that
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likely exhibits the canonical wrap-around CaM binding.44 This leaves some uncertainty
about the physiological stoichiometry of CaM binding to CaN, at important aspect of
CaM regulation of CaN for us to understand.
CaN’s CaMBR is located in the regulatory domain (RD) of CaN. The CaMBR begins 20
residues from the end of the CnBBH and ends 52 residues from the beginning of the AID.
Trypsin digests and other hydrolysis experiments by Manalan and Klee, and Yang and
Klee, respectively, demonstrated that the RD is readily hydrolyzed, showing that it is
flexible and accessible in nature.58,71 In the crystal structure of full length CaN the
electron density for the RD and C-terminal tail (CT) are missing suggesting that these
regions are highly mobile.52 Additionally, Romero and Dunker noted that the sequence of
the RD, enriched in charged and polar residues, gives it the potential to be disordered.72
Work by Rumi-Masante et al. showed by H/D exchange mass spectrometry and circular
dichroism spectroscopy that a fragment corresponding to CaN’s RD, AID, and CT (RDAID-CT) is disordered in the absence of CaM, though the AID is well-ordered in fulllength, inactive CaN.73 The RD portion of this fragment contains the CaM binding region
and the 52 residues that separate it from the AID (Figure 1.7). Canonically, CaM’s two
lobes wrap around its target site and induce α-helix in that sequence. Knowing now that
the overall RD is disordered, this leaves 52 residues of disorder between the end of the
CaMBR and the beginning of the AID, suggesting that CaM binding would not be able to
forcibly remove the AID from the active site. How then does CaM activate CaN with its
CaMBR and AID 52 residues apart and with those 52 residues being disordered?
The trypsin digests performed by Manalan and Klee, aside from demonstrating that the
RD is flexible and accessible to proteases, also suggested that the RD of CaN undergoes a
large conformational change upon CaM binding as the highly unprotected RD becomes
protected from trypsin digest when CaN is preincubated with CaM.71 Rumi-Masante et al.
also showed that upon CaM binding, ~50 residues within the RD become protected from
H/D exchange and that the RD gains approximately fifty residues of α-helicity.73 About
half of these residues reside in the CaMBR while the remainder are C-terminal to the
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CaMBR, between it and the AID. The high protection and α-helicity of the CaMBR when
CaM is bound is expected given the very tight binding between CaM and CaN (KD
~1pM) and the manner in which CaM typically binds its targets.44 The protection and
helicity in the region between the CaMBR and AID, suggested by RD protection in
Manalan and Klee’s CaN/CaM trypsin digests and confirmed by Rumi-Masante et al.,
suggests a larger scale structuring than just the sequence CaM directly binds.71,73
Exploration of the Regulatory Domain and Regulatory Domain/CaM interactions:
Dissertation Overview
CaN signaling has been demonstrated to be important in many signaling pathways and
tissues. Its interactions have been well studied, especially given its importance as the
target for immunosuppressant drugs. However, there is still much we do not understand
about the CaN protein itself, specifically concerning CaN’s regulatory domain (RD)
interaction with CaM. Through work from multiple groups, we know that the RD is
disordered in the absence of CaM but undergoes an ordering conformational change upon
CaM binding.52,58,71-73 Beyond this, there is much we do not understand about the
interaction.
What is the shape of the RD alone? To term a protein or a protein region “disordered”
only tells us that the protein does not adopt a well-ordered tertiary structure. Within this
definition, the protein can exist anywhere from an ensemble of completely disordered
string-like shapes to a molten-globule shape that has secondary structure, but where the
tertiary structure is ill-defined. We know from the work done by Rumi-Masante, et al.
that the RD is not on the molten-globule end of the disorder spectrum as CD spectra of
the RD -AID-CT indicate it has no persistent secondary structure.73 However, the
question remains, is the RD more compact in shape or extended? Chapter three of this
work explores the shape of the RD in the absence of CaM in order to help characterize its
disordered state. Chapter three also investigates the overall shape of the CaM:RD
complex. Fluorescence anisotropy, fluorescence correlation spectroscopy (FCS), and
circular dichroism (CD) spectroscopy are all employed in this endeavor.
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Chapter four delves into the stoichiometry of the CaM:RD complex. As noted, the
stoichiometry of this complex seems to exist at 2:2 in crystal structures; at both 2:2 and
1:1 in solution work, with 1:1 being the dominant species; and at 1:1 in hydrodynamic
studies.44,70,74,75 In an attempt to reconcile these views I employ crystallography to
investigate the structure of CaM bound to a peptide of CaN’s CaMBR (pCaN), and size
exclusion chromatography (SEC) is used to explore the CaM:RD stoichiometry. RD is
used in the SEC to determine if using a larger portion of CaN than just the CaMBR
would impact the stoichiometry of CaM binding.
Rumi-Masante, et al. demonstrated that the RD-AID-CT undergoes an ordering upon
CaM binding that extends beyond the CaMBR.73 There are ~50 residues that gain
structure upon CaM binding while the CaMBR is 24 residues in length. The remaining
order is gained in the region between the end of the CaMBR and the beginning of the
AID and is α-helical.73 Chapter five of this work investigates the nature of this ordering
and its impact on CaN activity using site-directed mutagenesis, CD spectroscopy, CD
thermal melts, and CaN phosphatase activity assays.
Chapter six serves as summation and further interpretation of the data presented in
previous chapters. Future experiments are also suggested to expand upon this work and to
further clarify the CaM:RD interaction both on its own and in the full context of
calcineurin.

Copyright © Victoria Beth Dunlap
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Figure 1.1 NFAT domains and phosphorylations
Schematic of NFAT domains is shown. Red circles are phosphorylation sites. Sequence of
CK1 docking site and CN docking site shown above. CK1: Casein Kinase 1; CN:
Calcineurin; NLS: nuclear localization signal; SP: SPxx repeat; SRR: serine rich region;
TAD: transactivation domain. Adapted and reprinted with permission from Elsevier: Li,
H., Rao, A., & Hogan, P. G. (2011). Interaction of calcineurin with substrates and
targeting proteins. Trends in cell biology, 21(2), 91–103. doi:10.1016/j.tcb.2010.09.011
License: 3145420796458
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Figure 1.2 Schematic of NFAT docked to CaN
CnA: light gray, CnB: dark gray, LxVP docking site: green, CaN active site: light blue,
PxIxIT docking site: yellow, NFAT: blue, Phosphorylations: red circles. Adapted and
reprinted with permission from PLOS: Grigoriu, S., Bond, R., Cossio, P., Chen, J. A., Ly,
N., Hummer, G., et al. (2013). The Molecular Mechanism of Substrate Engagement and
Immunosuppressant Inhibition of Calcineurin. (G. A. Petsko, Ed.)PLoS Biology, 11(2),
e1001492. doi:10.1371/journal.pbio.1001492.s007 License: Creative Commons
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Figure 1.3 Calcineurin domain structure
Structure of CaN with domains highlighted. PDBID: 1AUI.52 Catalytic domain: dark
blue; CnB binding helix: blue; Regulatory domain (RD): green, drawn, electron density is
missing from crystal structure; CaM binding region: orange rectangle, drawn, electron
density is missing from crystal structure;Autoinhibitory domain (AID): red; C-terminal
tail (CT): light gray, drawn, electron density is missing from crystal structure; Calcineurin
B (CnB): dark gray.
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Figure 1.4 Activation of calcineurin by calmodulin
CaN is maintained in an inactive state in the absence of CaM/calcium by the binding of
its AID at the active site. When calcium-loaded CaM binds to the disordered regulatory
domain (RD), the RD undergoes an ordering that removes the AID from the active site.
Adapted and reprinted with permission from Elsevier: Rumi-Masante, J., Rusinga, F. I.,
Lester, T. E., Dunlap, T. B., Williams, T. D., Dunker, A. K., et al. (2012). Structural basis
for activation of calcineurin by calmodulin. Journal of molecular biology, 415(2), 307–
317. doi:10.1016/j.jmb.2011.11.008 License: 3145460588532
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a.

b.

Figure 1.5 CaM structure
Calmodulin: green, MLCK CaM binding peptide: blue, calcium: red. a) Crystal structure
of CaM in the classical calcium loaded dumbbell form. PDB ID: 3CLN.76 b) NMR
structure of CaM bound to a peptide of a canonical CaM binding site in MLCK. PDB ID:
1CDL.77
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Figure 1.6 Structure of CaM with CaMBR of CaN, 2:2 stoichiometry
Crystal structure showing two CaM molecules bound to two peptides of the CaMBR
from CaN. One CaM molecule is shown in orange, and the other is shown in yellow.
CaMBR peptides from CaN are shown in red. PDB ID: 2W73.70 Adapted and reprinted
with permission from PLOS: Majava, V., & Kursula, P. (2009). Domain Swapping and
Different Oligomeric States for the Complex Between Calmodulin and the CalmodulinBinding Domain of Calcineurin A. (V. Majava & P. Kursula, Eds.) PLoS ONE, 4(4),
e5402. doi:10.1371/journal.pone.0005402.t003 License: Creative Commons
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Figure 1.7 Schematic of CaN domains and CaM binding region placement within the
regulatory domain
Linear schematic of CaN domains is shown with the RD and AID highlighted to show the
location of the CaMBR within the RD. Adapted and reprinted with permission from
Elsevier: Rumi-Masante, J., Rusinga, F. I., Lester, T. E., Dunlap, T. B., Williams, T. D.,
Dunker, A. K., et al. (2012). Structural basis for activation of calcineurin by calmodulin.
Journal of molecular biology, 415(2), 307–317. doi:10.1016/j.jmb.2011.11.008 License:
3145460588532
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Chapter 2: Materials and Methods
Materials
All chemicals were obtained from Sigma (St. Louis, MO) and were of the highest purity,
except where noted.
Plasmid expression vectors
The plasmid pETagHisCN containing the human αCaN A (with N-terminal His6 tag) and
B1 genes, together forming αCaN, was obtained from Addgene (Cambridge, MA). The
pETCaMI expression vector was generously provided by Professor Anthony Persechini
of the University of Missouri at Kansas City. An E. coli codon-optimized gene for the
human sequence RD construct was synthesized by Genscript (Piscataway, NJ). The RD
gene has added bases coding for MWG at the N-terminus and GCGGGLE at the Cterminus (Figure 2.1). The extra MWG creates the methionine start codon and allows for
protein concentration determination via the added tryptophan. The GCGGGLE creates a
glycine linker to the His6tag in the expression plasmid, adds a cysteine for the attachment
of maleimide fluorophores, and adds an XhoI restriction site. The RD was subcloned into
the pET303/CT-His vector that adds a C-terminal His6 tag (Invitrogen, Carlsbad, CA) by
using XbaI and XhoI to excise the RD gene from its original plasmid and to linearize the
pET303/CT-His vector and ligating the RD gene to linearized pET303/CT-His. The
subcloned gene was sequenced by ACGT inc. (Wheeling, IL) to ensure the presence and
integrity of the gene.
Mutagenesis
CaN-A447E, CaN-A451E, CaN-A454E, RD-A447E, RD-A451E, RD-A454E, and CaMD3C were all created from the original gene in its expression vector using Stratagene
QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies) (Figure 2.2). RDc
(Figure 2.3) was also created using materials from the Stratagene QuikChange II SiteDirected Mutagenesis kit, but the primer design and PCR was performed as follows78:
RDc was generated from the RD gene in pET303/CT-His. The deletion mutant removes
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everything after the first three residues of the RD up to the three residues before the
CaMBR. This is a 15 residue deletion. The primers were designed such that the reverse
primer matches the N-terminus but has an overlap segment that matches the beginning of
the region after the one to be deleted. The forward primer matches the segment after the
region to be deleted but has an overlap segment that matches a portion of the N-terminus
(before the deleted region) (Figure 2.4). The reaction mixtures were set up as the
Stratagene QuikChange II Site-Directed Mutagenesis kit calls for, but the PCR was
performed as in Table 2.1. All mutated genes were sequenced by ACGT inc. (Wheeling,
IL) to ensure the presence of the mutations and the integrity of the genes.
Expression and purification of recombinant CaN and CaN mutant proteins
The CaN and CaN mutant vectors were transformed into Escherichia coli BL21 (DE3)
CodonPlus RIL cells (Agilent Technologies, La Jolla, CA) for expression as follows:
Cells containing protein plasmid were grown overnight in 100mL Terrific Broth (TB, IBI
Scientific, Peosta, IA) under the selection of ampicillin (amp, 75µg/mL) at 37°C with
shaking. The following day, cultures were transferred to 900mL TB/amp and grown at
37°C with shaking until OD600 reached ~1.5. Protein expression was induced by adding
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5mM and
grown for four hours at 37°C with shaking. After expression, cells were pelleted by
centrifugation at 6000g for 7 minutes at 4°C. Pellets were stored at -20°C until
purification.
Cell pellets were thawed and resuspended in 1/40 of culture volume of lysis buffer
(20mM Tris pH 7.5, 10mM Imidazole, 200mM NaCl, 1mM PMSF) and one Complete
Protease Inhibitor Cocktail Tablet (Roche, Indianapolis, IN) was added. Lysozyme was
added to a final concentration of 125µg/mL and cell resuspension was incubated on ice
for 20 minutes. Cells were sonicated three times for 20sec each with 3sec on, 1sec off
pulse and 60% amplitude. Lysate was centrifuged at 25000g for 20min at 4°C and
0.45µm filtered before applying to a 10mL Ni-NTA column pre-equilibrated in binding
buffer (20mM Tris pH 7.5, 10mM Imidazole, 200mM NaCl). Column was washed with
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100mL of binding buffer and protein was eluted with 35mL elution buffer (20mM Tris
pH 7.5, 2mM CaCl2, 250mM Imidazole, 200mM NaCl). The elution was applied to a
CaM-Sepharose column (GE Healthcare, Piscataway, NJ) pre-equilibrated with Tris
column buffer (20mM Tris pH 7.5, 200mM NaCl, 2mM CaCl2). The column was washed
with 100mL of Tris column buffer and eluted with CaM-Seph elution buffer (20mM Tris
pH 7.5, 200mM NaCl, 4mM EGTA) and collected in 15 x 1.2mL fractions. Proteins had
their identities confirmed via mass spectrometry and purity confirmed by 14% SDSPAGE analysis. If necessary, protein was dialyzed into appropriate buffer using
SnakeSkin dialysis tubing (10kDa MWCO, Pierce/Thermo) and concentrated using
Amicon Ultra centrifugal filter units (10kDa MWCO; Millipore, Billerica,
Massachusetts). Protein concentrations were determined using either protein absorbance
at 280nm or using the bicinchoninic acid assay.79
Expression and purification of recombinant RD and RD mutant proteins
The RD and RD mutant vectors were co-transformed into Escherichia coli BL21 (DE3)
cells with the pETCaM1 vector. CaM is co-expressed with RD or RD mutants and then
removed during purification. When RD is expressed without CaM co-expression the
protein is degraded in cells before purification. Cells containing protein plasmids were
grown overnight in 100mL Terrific Broth (TB, IBI Scientific, Peosta, IA) under the
selection of ampicillin (amp, 75µg/mL) for RD and kanamycin (kan, 50 µg/mL) for CaM
at 37°C with shaking. The following day, cultures were transferred to 900mL TB/amp
and grown at 37°C with shaking until OD600 reached ~1.5. Protein expression was
induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration
of 0.5mM and grown for four hours at 37°C with shaking. After expression, cells were
pellet by centrifugation at 6000g for 7 minutes at 4°C. Pellets were stored at -20°C until
purification.
Cell pellets were thawed and resuspended in 1/40 of culture volume of lysis buffer
(20mM Tris pH 7.5, 10mM Imidazole, 200mM NaCl, 1mM PMSF) and one Complete
Protease Inhibitor Cocktail Tablet (Roche, Indianapolis, IN) was added. Lysozyme was
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added to a final concentration of 125µg/mL and cell resuspension was incubated on ice
for 20 minutes. Cells were sonicated three times for 20sec each with 3sec on, 1sec off
pulse and 60% amplitude. Lysate was centrifuged at 25000g for 20min at 4°C and
0.45µm filtered. Urea/thiourea buffer (5M urea, 2M thiourea, 20mM Tris, pH 7.5,
200mM NaCl, 10mM imidazole) was added to the lysate at 3x lysate volume. The urea/
thiourea is used to separate the RD from CaM, and a combination of urea and thiourea is
necessary as high (8M) urea concentration alone does not separate the RD and CaM. The
lysate is incubated in the urea/thiourea buffer at room temperature with stirring for 10
minutes before applying to a 10mL Ni-NTA column pre-equilibrated in urea/thiourea
buffer. 50mL 5M urea/ 2M thiourea buffer was added to the column, and the column was
incubated with shaking at room temperature for 30 minutes. The urea/thiourea
concentration was decreased from 7M to 0.125M by washing the column six times with
25mL of urea/thiourea buffer that was diluted by half each time. The column was washed
with 100mL of binding buffer (20mM Tris, pH 7.5, 200mM NaCl, 10mM imidazole) to
remove any remaining urea/thiourea. Protein was eluted with 35mL elution buffer (20mM
Tris pH 7.5, 2mM CaCl2, 250mM Imidazole, 200mM NaCl). The elution was applied to a
CaM-Sepharose column (GE Healthcare, Piscataway, NJ) pre-equilibrated with Tris
column buffer (20mM Tris pH 7.5, 200mM NaCl, 2mM CaCl2). The column was washed
with 50mL of Tris column buffer and eluted with CaM-Seph elution buffer (20mM Tris
pH 7.5, 200mM NaCl, 4mM EGTA) and collected in 15 x 1.2mL fractions. Proteins had
their identities confirmed via mass spectrometry and purity confirmed by 14% SDSPAGE analysis. If necessary, protein was buffer exchanged into appropriate buffer and
concentrated using Amicon Ultra centrifugal filter units (3kDa MWCO; Millipore,
Billerica, Massachusetts). Protein concentrations were determined using either protein
absorbance at 280nm or using the bicinchoninic acid assay.79

23

Expression and purification of recombinant CaM and CaM mutant proteins
The CaM and CaM mutant vectors were transformed into Escherichia coli BL21 (DE3)
cells (Agilent Technologies, La Jolla, CA) for expression as follows: Cells containing
protein plasmid were grown overnight in 100mL Terrific Broth (TB, IBI Scientific,
Peosta, IA) under the selection of kanamycin (kan, 50µg/mL) at 37°C with shaking. The
following day, cultures were transferred to 900mL TB/kan and grown at 37°C with
shaking until OD600 reached ~1.5. Protein expression was induced by adding isopropyl
β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5mM and grown for
four hours at 37°C with shaking. After expression, cells were pellet by centrifugation at
6000g for 7minutes at 4°C. Pellets were stored at -20°C until purification.
Cell pellets were thawed and resuspended in 1/40 of culture volume of CaM lysis buffer
(20mM Tris pH 7.5, 2mM CaCl2, 200mM NaCl, 1mM PMSF) and one Complete
Protease Inhibitor Cocktail Tablet (Roche, Indianapolis, IN) was added. Lysozyme was
added to a final concentration of 125µg/mL and cell resuspension was incubated on ice
for 20 minutes. Cells were sonicated three times for 20sec each with 3sec on, 1sec off
pulse and 60% amplitude. Lysate was centrifuged at 25000g for 20min at 4°C and
0.45µm filtered before applying to a 10mL TAPP (2-trifluoromethyl-10-aminopropyl
phenothiazine) Sepharose column pre-equilibrated with TAPP loading buffer (10mM Tris
pH 7.5, 200mM NaCl, 20mM CaCl2, 1mM β-mercaptoethanol).80 The TAPP-Sepharose
was synthesized at the Center for Structural Biology Chemistry Core Facility, University
of Kentucky (supported in part by funds from National Institutes of Health National
Center for Research Resources grant P20 RR020171). The column was washed with
50mL TAPP loading buffer and the protein was eluted into 10 x 6mL fractions with
TAPP elution buffer (10mM Tris-HCl pH 7.5, 200mM NaCl, 10mM EGTA). Proteins had
their identities confirmed via mass spectrometry and purity confirmed by 14% SDSPAGE analysis. Calmodulin was dialyzed into 10mM ammonium sulfate for desalting
and lyophilized. Lyophilized protein was resuspended in the appropriate buffer and
0.2µm filtered. If necessary, protein was dialyzed into appropriate buffer using SnakeSkin
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dialysis tubing (10kDa MWCO, Pierce/Thermo) and concentrated using Amicon Ultra
centrifugal filter units (10kDa MWCO; Millipore, Billerica, Massachusetts). Protein
concentrations were determined using either protein absorbance at 280nm or using the
bicinchoninic acid assay.79
Peptides
The pCaN peptide for crystallographic studies (ARKEVIRNKIRAIGKMARVFSVLR)
corresponding to the CaM binding region in the RD of αCaN was purchased from
Genscript (Piscataway, NJ). pCaN peptide content was assumed to be 75% of weight and
peptide resuspended in the appropriate buffer. The pCaN peptide for fluorescence studies
(WGARKEVIRNKIRAIGKMARVFSVLRGGC) corresponding to the CaM binding
region in the RD of αCaN was purchased from Pi Proteomics (Huntsville, AL ). The Nterminal tryptophan was added to the native pCaN sequence for accurate peptide
concentration determination using absorbance at 280nm and for tryptophan fluorescence
measurements. The C-terminal cysteine was added for attachment of maleimide
fluorophores, if necessary. The N-terminal and two C-terminal two glycines were added
to act as a linker between the tryptophan or cysteine and remainder of the peptide.
Modified p-RII (WGGDLDVPIPGRFDRRV[pS]VAAE), from cAMP dependent protein
kinase regulatory subunit (type II), is the CaN substrate used in the phosphatase assays
and was obtained from Atlantic Peptides (Scarborough, ME).81,82 The N-terminal
tryptophan was added for accurate peptide concentration determination using absorbance
at 280nm, and the following two glycines were added to act as a linker between the
tryptophan and remainder of the peptide. pRII was resuspended in H2O and concentration
was determined by peptide absorbance at 280nm. Both peptides were purified using
reverse-phase HPLC, and their identities were confirmed using mass spectrometry.

25

Circular Dichroism
CD spectra and melts were collected at 20°C using a Jasco J-810 spectrapolarimeter
equipped with a Peltier heating block. Protein CD spectra were obtained in buffer
consisting of 20mM Tris, 200mM NaCl, and 2mM CaCl2 at a pH of 7.5. Samples
containing 15µM of protein or, if a complex was being measured, 15µM of each protein
were placed in a 1mm path length cuvette and CD spectra were taken. Each spectrum is
an average of four scans at a scan speed of 50nm/min with five to six independent spectra
taken for each sample. Errors are estimated to be no more than 3%.
CD melts were obtained using a buffer consisting of 20mM HEPES, 200mM NaCl, and
2mM CaCl2 at a pH of 7.5. Samples containing 15µM of protein or, if a complex was
being measured, 15µM of each protein were placed in a 1mm path length cuvette and
thermal melts were obtained with a heating rate of 1°C/min and were monitored at a
wavelength of 222 nm with reported melts being the average of five or six scans.
Fluorescence Labeling
To create CaM-FL (D3C-CaM with Alexa Fluor 488 label) and RD-FL-C (RD with Alexa
Fluor 488 label) protein to be labeled was combined with an 10x molar excess of TCEP
(Tris(2-carboxyethyl)phosphine hydrochloride), pH6.8 in 20mM Tris pH 7.5, 200mM
NaCl, and 2mM CaCl2 and incubated at room temperature for two hours. Alexa Fluor 488
C5 Maleimide (dissolved in water; Invitrogen, Carlsbad, CA) was added to the protein/
TCEP at a 10:1 fluorescent label:dye ratio, and the mixture was diluted to a final volume
of 1mL with 20mM Tris pH 7.5, 200mM NaCl, and 2mM CaCl2. Final reaction
concentrations: 60µM protein, 600µM TCEP, and 600µM fluorescent label. Labeling
reaction proceeded overnight, in the dark, at 4°C.
CaM-FL reaction was transferred to a 3mL, 3.5kDa MWCO Slide-A-Lyzer G2 dialysis
cassette (Pierce/Thermo) and dialyzed against 2L of 20mM Tris pH 7.5, 200mM NaCl,
and 2mM CaCl2 with stirring at 4°C seven times. Each dialysis proceeded for either four
hours or overnight. RD reaction was was applied to a CaM-Sepharose column (GE
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Healthcare, Piscataway, NJ) pre-equilibrated with Tris column buffer (20mM Tris pH 7.5,
200mM NaCl, 2mM CaCl2). The column was washed with 50mL of Tris column buffer
and eluted with CaM-Seph elution buffer (20mM Tris pH 7.5, 200mM NaCl, 4mM
EGTA) and collected in 15 x 1.2mL fractions. Alexa Fluor 488 concentration was
determined by absorbance at 495nm. Protein concentration was determined by
absorbance at 280nm with correction for fluorescent label absorption at 280nm.
Fluorescence Spectroscopy
Anisotropy of RD-FL-C (Alexa Fluor 488 label), RD-FL-N (tryptophan label), and CaMFL (Alexa Fluor 488 label) were measured using a K2 multifrequency phase fluorometer
(ISS; Champaign, IL) equipped with Glan-Thompson polarizers. Anisotropies of labeled
proteins were measured in 20mM Tris, pH 7.5, 200mM NaCl, 2mM CaCl2. The
anisotropies of 100nM RD-FL-C ± 300nM CaM, 100nM CaM-FL ± 300nM RD, and
100nM CaM-FL ± 300nM pCaN were measured with excitation at 495nm and emission
at 520nm. The anisotropies of 10µM RD-FL-N ± 30µM CaM and 10µM pCaN ± 30µM
CaM were measured with excitation at 295nm and emission at 350nM. For each protein/
complex three independent samples were measured with 30 iterations for each sample.
The translational diffusion coefficients of 20nM RD-FL-C ± 100nM CaM were
determined by fluorescence correlation spectroscopy (FCS) using an ALBA Fluorescence
Fluctuations Spectroscopy System (ISS, USA) fitted to an inverted Nikon, Model Ti-U
microscope and 488 nm and 635 nm continuous wave diode lasers. Diffusion coefficients
are the averages of three independent samples. FCS was performed by Xiaolu Zhang in
the Department of Chemistry at the University of Kentucky.
Size-exclusion chromatography
Analytical size-exclusion chromatography (SEC) was performed on RDc, CaM, and
CaM:RDc using a Superdex 75 10/300 GL column on an ÄKTA FPLC both from GE
Healthcare Lifesciences (Pittsburgh, PA). The running buffer used was 20mM Tris pH
7.5, 200mM NaCl, 50mM CaCl2. All proteins were buffer exchanged into running buffer
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and 0.2µm filtered before use. Column elution was monitored at 280nm for the presence
of protein. 100µL of 232µM RDc was run through the column in triplicate, and 100µL of
1.1mM CaM was run through the column in triplicate. CaM was used at a much higher
concentration than RDc because CaM contains no tryptophans, but does have two
tyrosines, making its absorbance at 280nm much lower than RDc which contains a
tryptophan. 100µL of CaM:RDc complex was run under two different conditions: 1)
excess RDc: 200µM RDc and 150µM CaM and 2) excess CaM: 150µM RDc and 200µM
CaM. Gel filtration standards were purchased from Bio-Rad (Hercules, CA), and one
18mg vial was dissolved in 0.5mL running buffer, 0.2µm filtered, and 100µL run on the
column.
Structure determination
Crystals of the CaM:pCaN complex were grown using hanging-drop vapor-diffusion
experiments by Emily Holbrook, NSF-REU student. Purified CaM was combined with a
slight molar excess of pCaN and concentrated to 10 mg/ml in 10mM Tris pH 7.5, 2.3mM
CaCl2. Protein was mixed in a 3:1 ratio of protein:mother liquor containing 24% PEG
1000, 20% glycerol in a final volume of 200 nL using a mosquito crystallization robot
(TTPLabtech). Crystals formed in 2-3 weeks at 18°C. Crystals were harvested, passed
through mother liquor supplemented with 10% glycerol, and flash frozen in liquid
nitrogen. Diffraction data to 1.95 Å was collected at the SER-CAT ID-22 beamline of the
Advanced Proton Source, Argonne National Laboratories (Table 2.2). Data were
processed using HKL2000.83
An initial molecular replacement solution was obtained using PHASER with calmodulin
N-terminal and C-terminal lobes (PDB=2W73) as the search model with the assistance of
Dr. Craig Vander Kooi.84 Clear electron density for pCaN was observed and manually
built. Iterative model building and refinement using COOT85 and Refmac586 by Tori
Dunlap and Hou-fu Guo produced a final refined model (Table 2.2). Molecular graphics
were prepared using Pymol.
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Calcineurin phosphatase assays
Phosphatase assays were performed in assay buffer, 50mM Tris, pH 7.5, 100mM NaCl,
0.5mM DTT, 0.025% NP-40, 0.5mM CaCl2 (Enzo Life Sciences, Farmingdale, NY).
50uL reactions contained 30nM CaN or mutant, 90nM CaM, and 0-800µM p-RII as
substrate. Reactions were initiated with p-RII and proceeded for 7min at 30°C. Reactions
were terminated and free phosphate was detected by addition of 100uL Biomol Green
Reagent (Enzo Life Sciences), incubation for 20min, and absorbance measured at 620nm.
Each assay was performed in five replicates. Kinetic constants were determined by fitting
substrate vs initial velocity plots to the Michaelis-Menton equation using KaleidaGraph
software.

Copyright © Victoria Beth Dunlap
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380

390

MWGSDDELGSEEDGFDGATAAAR
400

410

KEVIRNKIRAIGKMARVFSVLRE
420

430

ESESVLTLKGLTPTGMLPSGVLS
440

450

460

GGKQTLQSATVEAIEADEAIKGF
SPQHKITGCGGGLEHHHHHH
Figure 2.1 Sequence of the RD construct
RD: green, CaMBR: orange, portion of AID: red, extraneous sequence: gray. Extraneous
sequence was added for protein expression and purification purposes.
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380

390

MWGSDDELGSEEDGFDGATAAAR
400

410

KEVIRNKIRAIGKMARVFSVLRE
420

430

ESESVLTLKGLTPTGMLPSGVLS
440

450

460

GGKQTLQSATVEAIEADEAIKGF
SPQHKITGCGGGLEHHHHHH
Figure 2.2 Sequence of the RD portion of CaN and RD mutants
The RD portion of the sequence for the following CaN or RD constructs is shown: CaNA447E, CaN-A451E, CaN-A454E, RD-A447E, RD-A451E, RD-A454E. The underlined
alanines are the amino acids that have been mutagenized to glutamates in the constructs
listed. RD: green, CaMBR: orange, portion of AID: red, extraneous sequence: gray.
Extraneous sequence was added for protein expression and purification purposes.
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400

410

430

440

MAGTAAARKEVIRNKIRAIGKMARVFSVLR
420

EESESVLTLKGLTPTGMLVLSPSGGGKQTL
450

460

QSATVEAIEADEAIKGFSPQHKITGWGGGL
EHHHHHH
Figure 2.3 Sequence of the RDc construct
Sequence of RDc construct is shown. The sequence is the same as RD3 except there is a
15 residue deletion at the location of the arrow (the 15 residues have been removed from
the sequence). RD: green, CaMBR: orange, portion of AID: red, extraneous sequence:
gray. Extraneous sequence was added for protein expression and purification purposes.
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Figure 2.4 Schematic of primer design to create the RDc deletion mutant
The primers were designed such that the reverse primer matches the N-terminus (core
segment) but has an overlap segment that matches the beginning of the region after the
one to be deleted. The forward primer matches the segment after the region to be deleted
(core segment) but has an overlap segment that matches a portion of the N-terminus
(before the deleted region). Melting temperature of the core segments should be ~60° and
melting temperature of the overlap segments should be ~30°C.
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Table 2.1: PCR cycles for generation of the RDc mutant
#cycles

Temp

Time

1

95C

30s

25

95C
55C
72C

30s
1min
6min

1

72C

10min

1

6C

end
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Table 2.2: Data collection and refinement statistics

Data collection
Beamline
Space group
Wavelength
Unit-cell parameters
Unique reflections
Completeness (%)
Resolution (Å)
Rmerge (%)
Redundancy
I/σ(I)

APS 22-ID
C2 2 21
0.9792
59.408, 73.934, 162.382
15796
91.1 (69.6)
1.95 (2.02-1.95)
9.8 (37.5)
5.5 (3.2)
14.4 (3.37)

Refinement
Resolution Limits (Å)
# reflections/# to compute Rfree
R (Rfree)
# protein residues
# solvent molecules
# calcium molecules

19.12-1.95
14985/801
23.0 (28.1)
166
58
4

Ramachandran
Most favored
Allowed
Disallowed

97.6
2.4
0

RMS deviation
Bond, Å
Angle, °

0.007
1.064
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Chapter 3: Disorder to order in the regulatory domain of calcineurin
Introduction
Intrinsically disordered proteins (IDP) are those that do not possess well-defined threedimensional structures in aqueous solution.87,88 This also includes intrinsically disordered
regions (IDRs), disordered segments of polypeptide chain within an otherwise wellordered protein. IDRs are extremely common and play crucial roles in human biology,
including roles in transcription, signaling pathways, and the immune system.87,89-92 As
such, IDRs are implicated in a number of human disease states such as cardiovascular
disease,93 protein aggregation diseases,90 and cancer.94
IDRs exist in conformational ensembles as, by definition, they do not have well-defined
three-dimensional structure, but this does not mean that they are devoid of any structure.
Disorder is a continuum from extended polypeptide chain to a molten globule state. Babu
et al. have defined four types of disordered states along the disorder continuum that are
useful for characterizing IDRs, from more disorder to less disorder: unstructured and
extensive disorder, restricted ensemble of conformations, partially populated secondary
structure and linear peptide motif, and regulated partial or complete folding upon binding.
95

Where in this continuum an IDR exists is highly dependent on its sequence. In general,

IDRs have a low number of hydrophobic residues and a higher polar/charged residue
content as compared to well ordered proteins, but the net charge of the protein affects the
nature of the disorder.87-89,92,96 Sequences enriched in polar amino acids and deficient in
hydrophobic residues form compact, globular conformations, closer to the “more
ordered” end of the continuum.95,97,98 As the net charge per residue increases, there is a
transition from globular to loosely packed ellipsoidal coils, a “less ordered”
conformation.95,99,100
The very important calcium signaling protein calmodulin (CaM) appears to take
advantage of IDRs at the “regulated partial or complete folding upon binding” end of the
disorder spectrum.

101

CaM has ~300 known binding targets66 including important

enzymes such as calcineurin,73 CaM kinase I,102 and smooth muscle myosin light chain
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kinase.103 When CaM binds a target it induces, in most but not all cases, α-helical
structure in the CaM binding region (CaMBR).77,104 Radivojac et al.101 employed a
bioinformatics approach to predict that unbound CaMBR sequences are often within
disordered regions, and we have previously demonstrated that these regions often have a
propensity towards α-helicity.69
The serine/threonine protein phosphatase calcineurin (CaN) is regulated by CaM in this
folding-upon-binding manner.73 CaN is important in several developmental processes as
well as learning and memory, skeletal muscle growth, and immune system activation.4
Inappropriate CaN regulation is implicated in Alzheimer’s disease6, Down syndrome7,
and cardiac hypertrophy.8,9 CaN is a heterodimer composed of an A-chain and a B-chain.
The ~60-kDa A-chain consists of the catalytic domain, B-chain binding helix, regulatory
domain (RD), an autoinhibitory domain (AID), and a C-terminal tail (CT) (Figure 3.1).55
The CaM binding region (CaMBR) is a 24 residue stretch within the regulatory domain.
The 19-kDa B-chain is structurally homologous to CaM and binds four calcium ions.57
There are three dominant CaN isoforms: the neuron specific αCaN, ubiquitous βCaN, and
the testes specific γCaN.58 Here, we discuss αCaN, and further use of CaN will refer to
αCaN.
Previous proteolysis work by Yang et al. and Manalan et al., the crystal structure of CaN,
and sequence analysis work all suggest that the RD may be disordered.52,56,71,72 RumiMasante et al. used CD spectroscopy and hydrogen-deuterium exchange mass
spectrometry (HXMS) to show that a portion of CaN corresponding to the RD-AID-CT is
disordered in the absence of CaM but gains α-helical structure upon CaM binding.73 The
CaM induced structure occurs in both the CaMBR and in the region C-terminal, prior to
the AID. Given that CaM seems to prefer to bind IDRs and induce folding, that the RDAID-CT undergoes a disorder-to-order transition upon CaM binding, and that the RDAID-CT has a low net charge per residue of -0.04, it is likely that the RD of CaN exists in
a

disordered but compact, globular conformation that gains persistent secondary

structure upon CaM binding.
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In this work, we investigate the nature of the disorder and structure of the RD in the
absence and presence of CaM. We use only the RD of CaN (instead of the RD-AID-CT)
because this is the region that contains the CaMBR, and Rumi-Masante et al.
demonstrated that the structure gained upon CaM binding is only in this region (Figure
3.1).73 We performed CD spectroscopy on the RD ± CaM to ensure that we see the same
conformational change upon CaM binding in the RD that Rumi-Masante et al observed in
the RD-AID-CT.73 Additionally, we employed fluorescence anisotropy to probe the
rotational diffusion of the RD ± CaM using an RD construct with a fluorophore on the Cterminus (Alexa Fluor 488), RD-FL-C, and using an RD construct with a fluorophore on
the N-terminus (tryptophan), RD-FL-N. The tryptophan added to the N-terminus of the
RD is the only tryptophan in the molecule. We also measured the translational diffusion
of the RD ± CaM using RD-FL-C in fluorescence correlation spectroscopy (FCS). While
the RD likely exists as this compact, globular ensemble, our CD, anisotropy, and FCS
experiments demonstrate that the RD undergoes further collapse upon CaM binding.
CaM binding causes the RD to gain persistent α-helical secondary structure in which the
RD:CaM complex has a similar hydrodynamic radius to that of the RD or CaM alone.
Results
The RD of CaN is devoid of persistent secondary structure, but gains α-helix upon
CaM binding
It was shown by Rumi-Masante et. al. via circular dichroism (CD) spectroscopy and H/D
exchange mass spectrometry (HXMS) that the RD-AID-CT alone is disordered, and there
was no detectable gain of structure in the AID or CT upon CaM binding to the RD-AIDCT fragment.73 To analyze the secondary structure of the RD we obtained CD spectra of
the RD alone. The spectrum is consistent with that of an unstructured polypeptide chain
(Figure 3.2). CD spectra of CaM alone is highly α-helical, as evidenced by the strong
minima at 208nm and 222nm. This is consistent with the mostly α-helical CaM seen in
crystal structures.76,105-107
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When CaM is combined with an equimolar amount of a peptide corresponding to the
CaMBR of CaN (pCaN) there is an increase in helical content as is expected for CaM
binding to and inducing helix in a CaM-binding peptide (Figure 3.2). CaM binds to CaN
with a KD ~1pM, therefore the 15µM of both CaM and pCaN used should result in
essentially all protein being bound. Upon addition of an equimolar amount of RD to CaM
there is an increase in α-helix that is greater than the increase seen with CaM:pCaN
(Figure 3.2). This indicates that the RD gains α-helix upon CaM binding, both in the
CaMBR and in additional RD sequence. These data are similar to that seen by RumiMasante et.al. for CaM, pCaN:CaM, RD-AID-CT, and RD-AID-CT:CaM.73
pCaN:CaM anisotropy
The anisotropy of the tryptophan of pCaN was measured in the absence and presence of
CaM (Figure 3.3a, Table 3.1). The anisotropy of pCaN alone was 0.033 ± 0.010 and
increases to 0.182 ± 0.017 with the addition of CaM. This is consistent with previously
reported anisotropy measurements of a tryptophan containing peptide from MLCK
binding to CaM, ~0.057 for the MLCK peptide alone to ~0.180 when CaM was added.103
For comparison, the anisotropy of CaM-FL (Alexa Fluor 488 label) was measured in the
absence and presence of pCaN (Figure 3.3a, Table 3.1). The anisotropy of CaM alone was
0.150 ± 0.012 and was 0.151 ± 0.002 with pCaN. The consistency of CaM anisotropy
with or without pCaN is to be expected given that the increase in size that comes from
binding of the 3.3kDa pCaN to the 16.7kDa CaM is small. Also, calcium loaded CaM
exists as an extended conformational ensemble that typically binds by wrapping around
its target peptide. This collapse of CaM around its target decreases the apparent volume
of CaM which increases the rotational diffusion, decreasing anisotropy. The KD of CaM
binding to CaN is ~1pM.44 With our measurements using 10µM of tryptophan fluorescent
proteins, 100nM of Alexa Fluor 488 fluorescent proteins, and a 3x excess of the nonfluorescent protein in complexes, essentially all fluorescent protein should be bound in
the cases where complexes are measured.
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Fluorescence anisotropy is a measurement of the rotational diffusion of a fluorophore.
When measuring the anisotropy of a protein labeled with a fluorophore the anisotropy is
influenced by both the rotational diffusion of the protein that the fluorophore is attached
to and the rotational diffusion of the fluorophore, independent of the protein. We attribute
the larger anisotropy of pCaN:CaM as compared to pCaN:CaM-FL to differences in the
rotational diffusion of the fluorophores, independent of the proteins. When CaM binds
pCaN, pCaN forms an α-helix that is buried within CaM, and the pCaN tryptophan is at
its N-terminus. Conversely, the Alexa Fluor 488 is attached to the N-terminal end of CaM
which is not buried and is likely more flexible. Therefore, the pCaN tryptophan would
experience less rotational freedom than the CaM Alexa Fluor 488, increasing its
anisotropy.
RD:CaM anisotropy
The anisotropy of RD-FL-C (Alexa 488 label, C-terminus) is 0.091 ± 0.002 whereas the
anisotropy of CaM-FL is 0.150 ± 0.004 (Figure 3.3b, Table 3.1). The lower RD-FL-C
anisotropy is due to the smaller RD size (MW=11.8 compared to CaM MW=16.7kDa),
but it also suggests that the fluorophore has more rotational freedom from being in a
disordered environment, as one would expect for the disordered RD. The RD-FL-C
anisotropy increases to 0.118 ± 0.008 with the addition of CaM. Comparatively, the
anisotropy of CaM-FL bound to RD is 0.172 ± 0.04 (Figure 3.3b, Table 3.1). The increase
in anisotropy for either protein alone (RD-FL-C:CaM = 0.027, RD:CaM-FL = 0.022) is
small when one considers that the increase in size from single protein to complex is close
to a doubling of size, depending on the protein being measured. This suggests that, while
there is an increase in molecular weight due to the complexation of the two proteins, that
increase is offset by a collapse of both molecules. For CaM, it exists in an extended
conformational ensemble when not bound, and wraps around the RD, decreasing its
hydrodynamic radius. The RD exists in a disordered state that collapses to a smaller
hydrodynamic radius upon CaM binding. Additionally, while both anisotropies increase
comparably, the anisotropy of RD-FL-C:CaM is considerably lower than that of
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RD:CaM-FL. This suggests that, while binding to CaM increases the anisotropy of RDFL-C, the fluorophore remains in a more disordered environment as compared to the
fluorophore on CaM when CaM-FL binds RD.
We also measured the anisotropy of RD-FL-N (tryptophan label, N-terminus) with and
without CaM as a comparison to the anisotropy of RD-FL-C with the fluorescent label on
the C-terminus. The anisotropy of RD-FL-N is 0.096 ± 0.020; comparable to the 0.091 ±
0.002 of RD-FL-C. When CaM is added, the anisotropy of RD-FL-N increases to 0.149 ±
0.044 which is a considerably larger increase than RD-FL-C upon CaM addition, a 0.053
increase for RD-FL-N compared to a 0.027 increase for RD-FL-C. This suggests that the
N-terminal end of the RD becomes more restricted upon CaM binding as compared to the
C-terminal end of the RD. This is expected given that the N-terminal tryptophan is 20
residues from the beginning of the CaMBR whereas the C-terminal Alexa Fluor 488 label
is 55 residues from the end of the CaMBR.
Translational diffusion of RD ± CaM
We obtained diffusion coefficients for RD-FL-C ± CaM using fluorescence correlation
spectroscopy (FCS). The diffusion coefficient for RD-FL-C is 77.4 ± 0.6µm2/sec and for
RD-FL-C:CaM is 74.4 ± 9.2µm2/sec (Table 3.1). The translational diffusion for both the
RD-FL-C alone and complexed with CaM are essentially equivalent, within the error of
the measurement. While the protein concentrations used for FCS are low, 20nM RD-FLC ± 100nM CaM; we are confident that the RD-FL-C and CaM are bound as the KD for
CaM:CaN binding is ~1pM.44 The equivalent translational diffusion coefficients for RDFL-C alone and bound to CaM are consistent with our anisotropy data, suggesting that
the complex, while larger in molecular weight, has a similar hydrodynamic radius to
either CaM or RD alone.
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Discussion
Intrinsically disordered regions (IDRs) are sections of polypeptide chain within ordered
proteins that do not possess stable three-dimensional structure in aqueous solution.87,88
However, these regions are not devoid of structure but exist as conformational ensembles
whose shape can fall anywhere from extended polypeptide to molten globule. The
sequence of an IDR impacts its disordered shape.95 IDRs that are enriched in polar amino
acids but devoid in hydrophobic residues tend to form more ordered, compact, globular
conformations whereas those IDRs with high a high net charge per residue form less
ordered, loosely packed ellipsoidal coils.95,97-100 The calcium signaling protein
calmodulin takes advantage of IDRs that fall on the more ordered “regulated partial or
complete folding upon binding” end of the disorder spectrum.69,101 CaM has a tendency to
bind disordered regions, wrapping around the CaMBR of the target sequence and
inducing α-helix.

77,104

Calcineurin is one such protein that CaM binds. The CaMBR of

CaN is in its regulatory domain (RD). Studies by Rumi-Masante et al. showed that the
RD-AID-CT of CaN is disordered but gains α-helix upon CaM binding in both the
CaMBR and the region of the RD that is C-terminal to the CaMBR.73 In this work we
have explored the nature of the disorder and structure in the RD of CaN with and without
CaM.
We performed CD studies on the RD with and without CaM to ensure that the RD alone
behaves similarly to the RD-AID-CT studied by Rumi-Masante et al., as their HXMS
studies showed that the gain in structure the RD-AID-CT experiences upon CaM binding
occurs only in the RD.

73

Our CD studies demonstrated that the RD is unstructured and

gains α-helix upon CaM binding. This is consistent the work Rumi-Masante et al.
performed on the RD-AID-CT.73 Thus, the RD does undergo a disorder-to-order
transition upon CaM binding, gaining persistent α-helical secondary structure.
We did anisotropy studies with CaM, RD, and pCaN, a peptide corresponding to the
CaMBR of CaN, to investigate the rotational diffusion of the RD in its disordered state
and when bound to CaM. Anisotropy studies showed a large increase in the tryptophan
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anisotropy of pCaN upon CaM binding. This is expected given the binding of a 16.7 kDa
protein such as CaM to a small 3.3kDa peptide like pCaN. The anisotropy change is
consistent with that of CaM binding to a peptide of the CaMBR of MLCK.103 The
anisotropy of CaM with a fluorophore bound (CaM-FL, Alexa Fluor 488), however, does
not change upon binding pCaN. Canonically, CaM exists in an extended conformational
ensemble that collapses and wraps around its target peptide upon binding. Therefore,
upon binding pCaN, the molecular weight of the complex is not much larger than CaMFL alone and the apparent hydrodynamic radius is smaller than that of CaM-FL alone,
resulting in no change in observed anisotropy. Any change in CaM anisotropy upon RD
binding would be due to the effects of the RD sequence outside of the CaMBR.
An increase in anisotropy corresponds to a decrease in rotational diffusion of the
fluorophore. This can be due to an increase in hydrodynamic radius of the molecule to
which the fluorophore is bound, such as when the fluorophore bound molecule binds
another protein, as is the case when pCaN is bound by CaM. Alternatively, increased
anisotropy can be the result of a decrease in the rotational diffusion of the fluorophore
within the protein environment, such as when a fluorophore is bound to a disordered
region and that region becomes structured. These two factors both impact the anisotropy
of the RD in the absence and presence of CaM. We find that RD-FL-C has a lower
anisotropy as compared to CaM-FL. This is partially due to the smaller size of the RD
(11.7 kDa for the RD vs 16.7kDa for CaM), but is also due to the increased rotational
diffusion of the fluorophore caused by the flexibility of the disordered RD. The
anisotropy of CaM-FL increases upon binding RD as does the anisotropy of RD-FL-C
upon binding CaM. The increases in anisotropy are comparable (RD-FL-C:CaM = 0.027,
RD:CaM-FL = 0.022) and small for a change from 16.7kDa for CaM and 11.7kDa for RD
to a 28.4kDa complex, suggesting that the complex has a hydrodynamic radius similar to
either protein alone. However, the anisotropy of RD-FL-C bound to CaM is considerably
smaller than CaM-FL bound to RD, indicating that the fluorophore on RD-FL-C still
exists in a somewhat disordered environment in the RD-FL-C:CaM complex.
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We also measured the tryptophan anisotropies of RD-FL-N (tryptophan label, Nterminus) with and without CaM for comparison to RD-FL-C (Alexa Fluor 488 label, Cterminus) anisotropies. The two RD species had the same anisotropy in the absence of
CaM, but RD-FL-N:CaM had a larger anisotropy compared to RD-FL-C:CaM. This
suggests that the tryptophan of RD-FL-N becomes more restricted upon CaM binding
than the Alexa Fluor 488 on RD-FL-C does. HXMS data from Rumi-Masante et al.
demonstrated that the structure in the RD gained upon CaM binding occurs both in the
CaMBR and in the region C-terminal to the CaMBR.73 The structure gained in the region
C-terminal to the CaMBR is an amphipathic helix termed the distal helix. It is
hypothesized that the distal helix folds back onto CaM where its hydrophobic face
interacts with CaM, and this hairpin-like chain reversal removes the AID from the
catalytic site, activating CaN (Dunlap et al., submitted). Disruption of the hydrophobic
face of the distal helix diminishes CaN activity. However, the Tm for the helix is ~40°C,
indicating that the helix is only partially stable in in vivo. Our RD-FL-C anisotropy data
also suggest that the distal helix may be unstable as the change in anisotropy from RDFL-C to RD-FL-C:CaM suggests that the Alexa Fluor 488 label at the C-terminal end is
still in a flexible environment when CaM binds.
FCS measurements were taken to determine the translational diffusion coefficients of
RD-FL-C alone and complexed with CaM. The diffusion coefficients for RD-FL-C with
and without CaM were the same within the error of the experiment. This is consistent
with our anisotropy studies with RD-FL-C with CaM and CaM-FL with RD. The increase
in anisotropies from individual protein to complex was small, indicating little change in
apparent hydrodynamic radius. The absence of significant change in the translational
diffusion coefficient of RD-FL-C upon CaM binding also suggests that the hydrodynamic
radius of the complex is similar to that of RD-FL-C alone. While FCS experiments are
conducted at very low protein concentrations (20nM RD-FL-C ± 100nM CaM), we are
confident that RD-FL-C is binding CaM under these conditions as the KD for CaM:CaN
binding is ~1pM.44
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It was previously shown that the RD of CaN is disordered but gains structure upon CaM
binding.73 Our CD studies have confirmed the disorder of the RD and the gain of α-helix
seen in the RD by Rumi-Masante et al.73 Given the low net charge per residue of the RD,
one would expect it to exist as an ensemble of disordered but compact, globular
conformations.95,99,100 The RD likely exists as this compact, globular ensemble, but our
CD, anisotropy, and FCS experiments demonstrate that the RD undergoes further collapse
upon CaM binding, gaining persistent α-helical secondary structure in which the
RD:CaM complex has a similar hydrodynamic radius to that of the RD or CaM alone.

Copyright © Victoria Beth Dunlap
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Figure 3.1: Calcineurin domain structure and RD construct
a. Structure of CaN with domains highlighted. PDBID: 1AUI.52 b. Schematic of the RD
constructs used. Orange indicates the CaM binding region. The blue circle is the location
of the tryptophan in RD-FL-N, and the yellow circle is the location of the Alexa Fluor
488 in RD-FL-C. The black line indicates the region of the RD that is protected in HXMS
upon CaM binding as shown by Rumi-Masante et al.73
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Figure 3.2: RD, CaM, pCaN CD spectra
Far UV CD spectra collected at 20°C for RD, CaM, pCaN complexed with CaM, and RD
complexed with CaM.
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Figure 3.3: Fluorescence anisotropies
Fluorescence anisotropy measurements for a. pCaN, pCaN + CaM, CaM-FL, and CaMFL + pCaN; b. CaM-FL, CaM-FL + RD, RD-FL-C, RD-FL-C + CaM, RD-FL-N, RDFL-N + CaM. Error bars indicate the standard deviation across measurements. pCaN:
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peptide of the CaM binding region, CaM-FL: D3C-CaM with Alexa Fluor 488 covalently
linked to C3, RD-FL-C: RD with Alexa Fluor 488 covalently linked to a cysteine at the
C-terminus, RD-FL-N: RD whose anisotropy was measured using the tryptophan at the
N-terminus.
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Table 3.1: Anisotropies and diffusion coefficients of pCaN, CaM, RD, and complexes

Anisotropy

Diffusion Coefficient
(µm2/sec)

pCaN

0.033 ± 0.010

-

pCaN + CaM

0.182 ± 0.017

-

CaM-FL

0.150 ± 0.012

-

CaM-FL + pCaN

0.151 ± 0.002

-

CaM-FL + RD

0.172 ± 0.04

-

RD-FL-C

0.091 ± 0.002

77.4 ± 0.6

RD-FL-C + CaM

0.118 ± 0.008

74.4 ± 9.2

RD-FL-N

0.096 ± 0.020

-

RD-FL-N + CaM

0.149 ± 0.044

-
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Chapter 4: Stoichiometry of the calcineurin regulatory domain-calmodulin
complex
Introduction
Calcineurin (CaN) is a calcium/calmodulin (CaM) activated serine/threonine
phosphatase. It was originally identified by Wang and Desai,1 Watterson and Vanaman,2
and Klee and Krinks3 as an inhibitor of the CaM activated cyclic 3’,5’-nucleotide
phosphodiesterase. These groups demonstrated that CaN binds to, and thereby depletes,
CaM in brain tissue, preventing activation of cyclic 3’,5’-nucleotide phosphodiesterase
by CaM.
Since its discovery, CaN has been shown to play roles in cardiac, vasculature, and
nervous system development.4 CaN signaling is also necessary for learning and memory,
skeletal muscle growth, and immune system activation.4 Because of its roles in these
varied signaling systems inappropriate CaN regulation has been implicated in a number
of pathological states including Alzheimer’s disease,6 Down syndrome,7 and cardiac
hypertrophy.8,9 Additionally, CaN’s ability to dephosphorylate and activate the nuclear
factor of activated T-cells (NFAT) family of transcription factors makes it the target of the
immunosuppressant drugs FK506 and cyclosporin A.4,5
CaN is a heterodimer composed of a 57-61kDa A chain (CnA) and a 19kDa B chain
(CnB). CnA is composed of the catalytic domain, CnB binding helix, regulatory domain
(RD), autoinhibitory domain (AID), and C-terminal tail (CT) (Figure 4.1a).55 CnB is a
calcium binding EF hand protein that is structurally homologous to CaM. While CnB can
bind up to four calcium ions, it is constitutively bound to CnA, regardless of calcium
concentrations.57 There are three CaN isoforms: αCaN is found primarily in neurons,
βCaN is ubiquitous, and γCaN is testes specific.58 The pCaN and CaN regulatory domain
fragment (RDc) used in this work are from αCaN. Sequence numbering and use of “CaN”
refers to αCaN.
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Under resting calcium conditions, CaN is maintained in an inactive state by its
autoinhibitory domain (AID) bound to CaN’s catalytic site. When calcium levels rise,
calmodulin (CaM) binds calcium and then binds to the calmodulin binding region
(CaMBR) of CaN, located in the regulatory domain (RD) (Figure 4.1).56 In the absence of
calcium/CaM the RD is disordered, and CaM binding to CaN causes an ordering in the
RD that removes the AID from CaN’s catalytic site, activating the enzyme. 73
While there are several classes of sequences that CaM binds to, calcium loaded CaM
preferentially binds to basic, amphipathic, α-helical sequences (BAA sequences).44,66,67 In
some cases, as with CaN, the CaM target sequence is disordered but prone to α-helicity.69
Typically, when CaM binds BAA sequences, the CaM central linker helix becomes
flexible and its two CaM lobes wrap around the target to form a compact ellipsoid
(Figure 4.2 a,b).66,67
Ye et al. have published crystal structures of CaM bound to a peptide of the CaMBR of
CaN (Figure 4.1).74,75 We refer to the peptide of the CaMBR of CaN as pCaN. In these
structures the CaM:pCaN complex exists as a 2:2 structure in which the N-terminal lobe
of one CaM molecule and the C-terminal lobe of a second CaM molecule interact with a
pCaN peptide. The remaining C- and N-terminal lobes of the two CaM molecules,
respectively, interact with a second pCaN molecule (Figure 4.2c). The interaction occurs
such that a pCaN peptide and two CaM lobes interact in an antiparallel fashion. The Nterminal lobe of a CaM molecule interacts with the C-terminus of pCaN, and the Cterminal lobe of a second CaM molecule interacts with the N-terminus of pCaN. While
this 2:2 structure is different than the canonical “wrap-around” structure that generally
occurs with calcium loaded CaM binding to a BAA sequence, the 2:2 structure does
mimic a wrap-around structure when one considers only one half of the structure: an Nterminal CaM lobe and a C-terminal CaM lobe wrapped around a pCaN peptide.
Majava et al. also published a CaM:pCaN structure in which the stoichiometry is 2:2 that
is very similar to the structures by Ye et al.70 With the high resolution of their structure
(1.45Å) they are able to note that residues in both the hydrophobic pockets of CaM and
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the peptide have double conformations. In addition, the authors point out that low Bfactors are seen at the exterior of the complex as compared to the interior of the complex,
suggesting that crystal contacts are what stabilize the crystal form. Majava et al. also
performed small-angle X-ray scattering (SAXS) and size-exclusion chromatography
(SEC) on the CaM:pCaN complex. The SAXS data could only be fit to a 1:1 wrap-around
model, and the SEC showed a 1:1 complex. Ye et al. performed native-gel analysis on
CaM:pCaN and SEC on a CaM:pCaN fusion protein. Both techniques showed species
corresponding to 1:1 and 2:2 molecular weights, with the 1:1 species being the dominant
form.75 The work by both Ye et al. and Majava et al. suggest CaM:pCaN can exist as both
a 1:1 and 2:2 complex in solution, with a 1:1 complex being the dominant species, but is
2:2 in crystal structures.70,74,75
O’Donnell et al. have done extensive hydrodynamic work on CaM bound to pCaN from
βCaN (pCaNβ).44 The CaMBR of βCaN differs from that of αCaN by only one residue:
V395 in αCaN is I404 in βCaN. The sequence numbers are different due to an N-terminal
extension in CnA of βCaN. O’Donnell et al. used analytical gel chromatography to
determine the Stokes radii, sedimentation velocity studies to determine the sedimentation
coefficients, and NMR to determine 15N T2 relaxation times of CaM, CaM:pCaNβ, and
CaM:melittin. Melittin is a peptide that CaM is known to form a 1:1 complex with.
44,108,109

For each hydrodynamic experiment, CaM:pCaNβ and CaM:melittin were

identical, within the errors of the experiments. Compared to calcium-loaded CaM alone,
the CaM:peptide complexes had values consistent with a smaller hydrodynamic volume,
suggesting that, in solution, CaM:pCaNβ forms a collapsed, wrap-around 1:1 complex
similar to CaM:melittin.
In addition to hydrodynamic experiments, O’Donnell et al. used various NMR
experiments to examine some of the side-chain interactions in the CaM:pCaNβ complex.
They showed that P43 in the N-terminal lobe of CaM has an NOE with F419 at the Cterminal end of pCaNβ, the only aromatic in the peptide. This demonstrates that, in
solution, CaM binding to pCaNβ occurs in an antiparallel fashion such that the N-

53

terminal lobe of CaM binds the C-terminus of the peptide and the C-terminal lobe of
CaM binds the N-terminus of the peptide. All of the hydrodynamic and NMR data on
CaM:pCaNβ put forth by O’Donnell et al. are consistent with a collapsed, wrap-around
1:1 structure.
Taken together, the experiments performed by Ye et al., Majava et al., and O’Donnell et
al. suggest that CaM:pCaN exists as a 2:2 complex in solid-state crystallographic studies
but is predominantly a 1:1 complex in solution.44,70,74,75 In this work, we attempt to
reconcile the 2:2 solid-state complex and the 1:1 solution complex by doing
crystallography on CaM:pCaN and analytical size-exclusion chromatography on
CaM:RDc. RDc is a construct using the C-terminal portion of the RD from the beginning
of the CaM binding region to the beginning of the AID (Figure 4.1b). We used
CaM:pCaN for the crystallographic work so that our structure would be comparable to
the previous structures, and we used CaM:RDc for the size-exclusion chromatography to
determine if using a larger portion of CaN would impact the stoichiometry of CaM
binding in solution.
Results
Size-Exclusion Chromatography
We performed size-exclusion chromatography (SEC) on RDc, CaM, and the CaM:RDc
complex to determine the stoichiometry of the complex and to discover if the inclusion of
more of CaN than just the CaMBR used in previous SEC and crystallography studies
would impact the stoichiometry of the complex. In SEC runs of RDc alone and CaM
alone, RDc eluted at 11.87mL, and CaM eluted at 11.60mL, where the elution volume is
the volume at which the protein absorbance (280nm) peak was maximal (Figure 4.3a).
Comparing SEC of RDc and CaM to the SEC standards, we can see that both proteins
elute between the 44kDa standard (ovalbumin, 10.54mL) and the 17kDa standard
(myoglobin, 12.28mL) which is seemingly inconsistent with their molecular weights of
10.4kDa and 16.7kDa, respectively (Figure 4.3a, Table 4.1). However, in previous work
of CaM binding to a peptide of the CaM binding region of CaN (pCaN) it was shown that
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the elution volume for the complex is actually lower than for that of CaM alone.70 This is
attributed to the extended nature of calcium-loaded CaM in the absence of a binding
partner. The molecular weight standards are globular in nature whereas CaM is more
ellipsoidal, giving it a larger hydrodynamic radius than what would be expected for a
globular protein of the same size. This is consistent with the decrease in stokes radius of
CaM bound to peptide as compared to CaM alone seen by O’Donnell, et al.44 RDc alone
also appears at an elution volume that would suggest it has a higher molecular weight
than 10.4kDa. A construct of the RD-AID-CT of CaN has been shown to be disordered in
solution.73 The RDc would also be disordered and, similarly to CaM alone, extended in
conformation. Thus, RDc alone runs at a lower elution volume than expected due to its
extended nature compared to the globular nature of the standards.
The absorbance of CaM at 280nm is much stronger than RDc due to the use of a much
higher concentration of CaM (1.1mM CaM vs 0.232mM RD). This was done to improve
the CaM absorbance at 280nm since CaM has only two tyrosines and no tryptophans. The
tryptophan on RDc is extraneous sequence added to the construct for concentration
determinations. Additionally, in the CaM SEC trace there is a small peak around 8mL that
we attribute to protein aggregate as it elutes within the same volume as the 670kDa
standard (thyroglobulin, 8.06mL) (Table 4.1).
We performed SEC on the CaM:RDc complex under conditions of excess RDc
([RDc]=200µM, [CaM]=150µM) and excess CaM ([RDc]=150µM, [CaM]=200µM)
(Figure 4.3b). The complex eluted at 11.21mL under both conditions. In the complex with
excess RDc SEC trace there is a peak at 11.83mL, consistent with unbound RDc. There is
a shoulder on the CaM:RDc peak in the SEC trace of the complex with excess CaM that
is consistent with unbound CaM, but whose elution volume could not be determined. The
unbound CaM absorbance at 280nm in the excess CaM trace is much lower than the
unbound RD absorbance at 280nm in the excess RD trace due to the absence of
tryptophans in CaM. Additionally, in the SEC trace of the complex with excess CaM
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there is a small peak around 8mL as there was in the CaM alone SEC trace. As with the
CaM alone SEC trace, we attribute this peak to aggregate.
The CaM:RDc complex elutes at 11.21mL which is between the 44kDa standard
(ovalbumin, 10.54mL) and the 17kDa standard (myoglobin, 12.28mL), consistent with a
1:1 complex whose molecular weight would be 27.1kDa (Figure 4.3b, Table 4.1). If the
complex were 2:2 with a molecular weight of 54.2kDa the elution volume for the
complex would need to be between 8.70mL and 10.54mL, the elution volumes of the
158kDa and 44kDa standards (ɣ-globulin and ovalbumin, respectively) (Table 4.1). There
is a slight peak at ~10mL that would be consistent with a 2:2 complex, but this peak is
smaller than even the aggregate seen at 8mL and much, much smaller than the 1:1
complex peak. Therefore, in our SEC studies, the CaM:RDc has a 1:1 stoichiometry.
Crystal structure of the CaM:pCaN complex
The CaM:pCaN complex was crystallized in 24% PEG 1000, 20% glycerol and the
structure was determined at 1.95Å. Initial model building was done using the N-terminal
and C-terminal lobes of CaM from one of the CaM molecules in the 2:2 structure from
Majava et al. (PDB=2W73).70 Crystallography data and refinement statistics can be found
in Chapter 2, Table 2.2. The final structure reveals a 1:1 complex of CaM:pCaN, not a 2:2
structure like those determined by Ye et al. and Majava et al (Figure 4.2d).70,74,75 The
difference in stoichiometry between our 1:1 structure and the 2:2 structures is likely due
to the differences in crystal growing conditions. The crystals obtained by Ye et. al. were
grown in 0.2M ammonium phosphate, 0.1M citrate acid (pH 4.5) and 20% (w/v) PEG
3350; and the crystals from Majava et al. were grown in 30% PEG 400, 200 mM KCl,
and 100 mM Tris (pH 8.5).70,74,75
The structure maintains the antiparallel binding seen in those structures as the N-terminal
lobe of CaM interacts with the C-terminal end of pCaN, and the C-terminal lobe of CaM
interacts with the N-terminal end of pCaN. Additionally, many of the CaM:pCaN
intermolecular interactions are similar in our 1:1 structure and the 2:2 structures. I396 and

56

I400 of pCaN interact with M124 and F92 of CaM, respectively, in all structures (Figure
4.4). I403 of pCaN interacts with A88, V91, and V35 in CaM in all structures as well.
Finally, R408 of pCaN forms salt bridges with E83 and D80 of CaM in all structures.
Surprisingly, these R408:E83 and R408:D80 interactions occur between pCaN and the
linker helix of CaM that is ridged in the 2:2 complexes and bent in our 1:1 complex.
Calcium-loaded CaM has two major hydrophobic pockets that aromatic residues of BAA
sequences typically interact with. These are termed the FLMMn and FLMMc pockets:
F19, L32, M51, and M71 in the N-terminal lobe of CaM and F92, L105, M124, and
M144 in the C-terminal lobe of CaM, respectively (Figures 4.4, 4.5).44,110 In BAA
sequences with one aromatic residue, the aromatic is usually buried in the FLMMc
pocket, and in sequences with more than one aromatic residue one usually resides in each
FLMM pocket. The only aromatic residue in pCaN is F410, and it interacts with FLMMn
in the 2:2 complexes (Figure 4.5b).70,74,75 There are other, non-aromatic hydrophobic
contacts that pCaN makes with FLMMc in the 2:2 structures (noted above), but no
residues are buried in the pocket (Figure 4.4b). In our 1:1 CaM:pCaN complex F410 of
pCaN is not buried in either FLMM pocket, but instead ring-stacks with P43 of CaM.
O’Donnell et al (Figure 4.7).44 observed an NOE between F419 of pCaNβ (corresponding
to F410 of pCaN) and P43 of CaM, supporting evidence for the the F410:P43 ring
stacking we observe in our 1:1 complex. This NOE is not consistent with F410 binding in
the FLMMn pocket.
Instead of an aromatic in either FLMM pocket, our 1:1 CaM:pCaN complex shows M406
of pCaN buried in the FLMMn pocket, contacting all of the residues of the tetrad (Figure
4.5a). This appears to be the major stabilizing interaction for CaM:pCaN in our complex.
Similar to the 2:2 structures, I396 and I400 of pCaN interact with M124 and F92 of
FLMMc, but no residues are buried in the pocket (Figure 4.4a).
Discussion
Ye, et al. and Majava et al. have determined crystal structures of CaM:pCaN that
demonstrate a 2:2 complex wherein the N-terminal lobe of one CaM molecule and the C57

terminal lobe of a second CaM molecule interact with a pCaN peptide.70,74,75 The
remaining C- and N-terminal lobes of the two CaM molecules, respectively, interact with
a second pCaN molecule (Figure 4.2c). The interaction occurs such that a pCaN peptide
and two CaM lobes interact in an antiparallel fashion. The N-terminal lobe of a CaM
molecule interacts with the C-terminus of pCaN, and the C-terminal lobe of a second
CaM molecule interacts with the N-terminus of pCaN. While these structures are
obviously very different from the typical wrap-around binding that calcium-loaded CaM
displays with BAA sequences similar to CaN’s, they do mimic the wrap-around binding
in that an N-terminal lobe of CaM and a C-terminal lobe of CaM appear to wrap-around
the pCaN peptide.
Majava et. al performed SAXS and SEC on CaM:pCaN in solution, finding a 1:1
complex in both cases.70 Ye et. al. also performed SEC as well as native-gel analysis on
the CaM:pCaN complex and found both a 2:2 species and a 1:1 species, with the 1:1
complex being the dominant form.74,75 In addition, O’Donnell et al. did extensive
hydrodynamic and NMR studies on CaM with pCaN from βCaN (pCaNβ) and found only
a 1:1 complex.44 These studies, combined with the 2:2 crystal structures, suggest that
CaM:pCaN exists as a 2:2 complex in solid-state crystallographic studies but is
predominantly a 1:1 complex in solution.44,70,74,75 It seems that while a small population
of 2:2 complexes exists in solution, the dominance of the 2:2 complex in crystal
structures is likely due to the stabilizing effects of crystal contacts between complexes, as
described by Majava et. al.70
We sought to reconcile the 2:2 solid-state complexes and the 1:1 solution complexes by
doing crystallography on CaM:pCaN and analytical size-exclusion chromatography on
CaM:RDc, where RDc is a construct using the C-terminal portion of the RD from the
beginning of the CaM binding region to the beginning of the AID (Figure 4.1b).
In both our SEC and crystallographic data we observe a 1:1 complex. In SEC, when CaM
and RDc are run together, we see a peak that elutes between the volumes where the
44kDa and the 17kDa standards elute, consistent with a complex whose molecular weight
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would be 27.1kDa (Figure 4.3b, Table 4.1). If the complex were 2:2 with a molecular
weight of 54.2kDa the elution volume for the complex would need to be between
8.70mL and 10.54mL, the elution volumes of the 158kDa and 44kDa standards. This is
similar to what Ye et al. observe in their SEC and native-gel analysis, however, we see no
evidence of a 2:2 complex in our SEC.74,75 Majava et al. and O’Donnell et al. also
observed only 1:1 complexes in their CaM:pCaN solution studies.44,70
We performed SEC on CaM in complex with RDc, a piece of the regulatory domain of
calcineurin that is 56 residues longer than the 24 residue pCaN alone. The RDc construct
was used to determine if the increased sequence space would have any impact on the
stoichiometry of the complex. The extra length does not affect the complex stoichiometry,
but does change the behavior of the complex in SEC. Upon addition of the pCaN peptide
to CaM, Majava et al. observed a shift in the CaM SEC peak to a later elution volume
than that of CaM alone. This is counterintuitive as the addition of the peptide increases
the molecular weight, thereby one expects a shift to an earlier elution volume. However,
CaM’s extended dumbbell shape in the absence of ligand causes it to elute at a volume
consistent with a larger molecule. Therefore, when CaM wraps around the pCaN peptide,
the apparent molecular weight observed by SEC decreases because its hydrodynamic
radius has actually decreased.70,111
In our SEC studies, the elution volume of the CaM:RDc complex is shifted to an earlier
elution volume as compared to CaM alone, as is generally the case upon an increase in
molecular weight. The difference in our SEC as compared to the SEC done by Majava et
al. is due to the additional residues in the RDc.
The full RD of CaN is known to be disordered in the absence of CaM but gains structure
upon CaM binding.73 We used RDc, as opposed to the full RD, in our studies because
Rumi-Masante et al. had shown that the structure gained in the RD upon CaM binding
occurs C-terminal to the CaMBR. RDc is the majority of the RD but lacks 15 residues Nterminal to the CaMBR (Figure 4.1), a region shown by Rumi-Masante et al. not to gain
structure.73 In our SEC the CaM:RDc complex elutes at an earlier volume than either
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CaM or RDc alone, as expected. However, the decrease in elution time is not as much as
one would expect for essentially doubling the molecular weight of the complex compared
to either component alone. This suggests that, not only does CaM wrap around the RDc,
causing an apparent decrease in hydrodynamic radius, but the disordered RDc also
collapses upon CaM binding. We have previously shown that the α-helical structure
gained in the RD upon CaM binding is an amphipathic helix that diminishes CaN activity
when its hydrophobic face is disrupted. We hypothesized that, because the hydrophobic
face of the helix would need another hydrophobic surface to interact with, this helix folds
back upon CaM in a hairpin-like chain reversal upon CaM binding. The hairpin-like
chain reversal of this helix onto CaM is consistent with our SEC results that suggest a
collapse in RDc structure upon CaM binding (Dunlap et al., submitted).
In addition to our SEC studies, our crystallographic structure determination of the
CaM:pCaN complex demonstrates a 1:1 stoichiometry (Figure 4.2d). Previous
CaM:pCaN crystal structures have all had 2:2 stoichiometry.70,74,75 We have shown that a
1:1 stoichiometry also occurs in the crystallographic solid-state. Majava et al. pointed out
that low B-factors are seen at the exterior of their crystal complex as compared to the
interior of the complex, suggesting that crystal contacts stabilize the crystal form. In our
CaM:pCaN structure the low B-factors are observed on the inside of the complex,
particularly along the pCaN peptide and in the N-terminal lobe of CaM at the FLMMn
residues, where M406 of pCaN is buried. Therefore, the 1:1 complex seems to be
stabilized by the interaction of M406 with the FLMMn tetrad, not by crystal contacts.
While several of the intermolecular CaM:pCaN contacts are the similar between our 1:1
complex and the 2:2 complexes, there is one striking difference: the interaction of M406
of pCaN with the FLMMn pocket of CaM (Figure 4.5). This interaction is unique to the
1:1 complex not only because it is different from the 2:2 complexes, but also because it is
different than other known BAA:CaM interactions. When CaM interacts with BAA
sequences with one aromatic residue, the aromatic is buried in the FLMMc pocket, and in
sequences with more than one aromatic residue one usually resides in each FLMM
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pocket.44,110 In pCaN, the only aromatic residue is F410. In the 2:2 complexes, F410 is
buried in the FLMMn pocket, not the FLMMc pocket (Figure 4.5a). In our 1:1 complex
F410 is not buried in either pocket. M406 occupies the FLMMn hydrophobic pocket, and
the FLMMc pocket is unoccupied, though several small hydrophobic residues on pCaN
interact with the FLMMc tetrad (Figure 4.4a). F410 ring-stacks with P43 of CaM, an
interaction that is consistent with an NOE seen by O’Donnell et al. between F419 of
pCaNβ (F410 in pCaN) and P43 of CaM (Figure 4.7).
In their 2:2 crystal structure, Ye et al. observe interactions between M72 and M76 of CaM
with V409 and F410 of the pCaN peptide. They also observe salt bridges between R408
of the peptide and D80 and E83 of CaM.75 These interactions occur between the peptide
and the central linker helix of CaM (Figure 4.6b). In the 2:2 structures, the central linker
helix is one, extended helix, allowing one CaM molecule to interact with to pCaN
peptides. However, in our 1:1 structure we observe the linker helix bent as two helices
with a loop region in between, allowing CaM to wrap around pCaN. Ye et al. argue that
the interactions they see between pCaN and the central linker helix of CaM stabilize the
extended form of the linker helix, thereby stabilizing the 2:2 structure.
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In our 1:1

structure, we do not observe the interactions between M72/M76 of CaM and V409/F410
of pCaN. The shortest distance is from M76 to V409, and that distance is ~10Å. F410 is
on the opposite side of the pCaN helix from the two CaM methionines. However, our 1:1
structure does exhibit the salt-bridges between R408 of pCaN and D80/E83 of CaM
(Figure 4.6a). As these salt bridges are observed in both our 1:1 structure and the 2:2
structures, it is unlikely that they serve to stabilize the extended CaM central linker helix
seen in the 2:2 structures.
From the SEC we performed on CaM:RDc and the crystal structure we determined of
CaM:pCaN, we conclude that both exist as a 1:1 complex. Solution and hydrodynamic
studies by Ye et al., Majava et al., and O’Donnell et al. have shown that the predominate
form of CaM:pCaN in solution is the 1:1 species. Our SEC with CaM:RDc confirms this
and also demonstrates that an increase in the pCaN sequence to encompass the majority
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of CaN’s RD does not alter the stoichiometry of the complex. The crystal structure of
CaM:pCaN we determined is also of a 1:1 complex; this is in contrast to the previously
reported 2:2 CaM:pCaN structures. However, our 1:1 complex of one CaM molecule
wrapping around one pCaN peptide is consistent with the NMR work and extensive
hydrodynamic work done by O’Donnell et al. as well as previously published CaM:BAA
structures.44,110 Our 1:1 CaM:pCaN crystal structure and SEC data for the CaM:RDc
complex strongly suggest that a single CaM molecule is responsible for binding to and
activating CaN.

Copyright © Victoria Beth Dunlap
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Figure 4.1: Calcineurin domain structure and RDc construct
a. Structure of CaN with domains highlighted. PDBID: 1AUI.52 b. Sequence of RDc
construct RD: green, CaMBR: orange, portion of AID: red, extraneous sequence: gray.
Extraneous sequence was added for protein expression and purification purposes.
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Figure 4.2: CaM and CaM:target peptide structures
a. Structure of calcium loaded CaM; 3CLN.76 b. Structure of CaM bound to smMLCK
CaMBR; 1CDL.104 c. 2:2 structure of CaM bound to pCaN; 2R28
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d. 1:1 structure of

CaM bound to pCaN; structure solved in this work. CaM: green, calcium: red, CaMBR
peptide: blue
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a.

b.

Figure 4.3: CaM, RDc size-exclusion chromatography
Size-exclusion chromatography traces of a. CaM alone and RDc alone and b. CaM:RDc
complex in excess of RD or excess of CaM. In each graph, the vertical lines with 1, 2, 3,
and 4 above them indicate the elution volume of the standards listed in Table 4.1.
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Figure 4.4: FLMMc binding pocket interactions
FLMMc binding pocket interactions in a. 1:1 structure of CaM bound to pCaN; structure
solved in this work. b. 2:2 structure of CaM bound to pCaN; 2R28 75 c. Structure of CaM
bound to smMLCK CaMBR; 1CDL.104 CaM: green, CaMBR peptide: blue.
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Figure 4.5: FLMMn binding pocket interactions
FLMMn binding pocket interactions in a. 1:1 structure of CaM bound to pCaN; structure
solved in this work. b. 2:2 structure of CaM bound to pCaN; 2R28 75 c. Structure of CaM
bound to smMLCK CaMBR; 1CDL.104 CaM: green, CaMBR peptide: blue.
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Figure 4.6: pCaN R408 salt bridges with CaM D80 and E83
Salt bridge interaction between R408 of pCaN and D80, E83 of CaM in a. 1:1 structure
of CaM bound to pCaN; structure solved in this work. b. 2:2 structure of CaM bound to
pCaN; 2R28 75 CaM: green, CaMBR peptide: blue.
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Figure 4.7: pCaN F410 and CaM P43 ring stacking
Ring stacking interaction between F410 of pCaN and P43 of CaM in the 1:1 structure of
CaM bound to pCaN; structure solved in this work. CaM: green, CaMBR peptide: blue.
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Table 4.1: Size exclusion chromatography standards run on the Superdex 75 10/300 GL
column
Standard

Molecular Weight (kDa)

Elution Volume (mL)*

1. Thyroglobulin (bovine)

670

8.06

2. ɣ-globulin (bovine)

158

8.70

3. Ovalbumin (chicken)

44

10.54

4. Myoglobin (horse)

17

12.28

*Elution volume is the volume at which the protein absorbance (280nm) was maximal
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Chapter 5: The distal helix in the regulatory domain of calcineurin is
important for calcineurin-regulatory domain stability and calcineurin
function
Introduction
The calcium signaling protein calmodulin (CaM) is important in numerous signaling
pathways and is known to have approximately three-hundred binding targets.66 Among
these targets are the calmodulin activated kinases such as CaM kinase I (CaMKI), CaM
kinase II (CaMKII), CaM kinase kinase (CaMKK), and myosin light chain kinase
(MLCK).112 CaM activated kinases possess an autoinhibitory domain (AID) that occludes
the catalytic site, rendering the kinase inactive. When cellular calcium levels rise CaM
binds four calcium ions and then binds the kinase at a site just C-terminal to the AID, the
CaM binding region (CaMBR), causing a conformational change that removes the AID
from the catalytic site, activating the kinase (Figure 5.1).113
In contrast to the CaM activated kinases, there is only one known CaM activated
phosphatase, the serine/threonine phosphatase calcineurin (CaN).1-3 CaN is involved in
several developmental processes including formation of the cardiac, vasculature, and
nervous systems.4 CaN is also necessary for learning and memory, skeletal muscle
growth, and immune system activation.4 As such, inappropriate CaN regulation has been
implicated in pathological states such as Alzheimer’s disease6, Down syndrome7, and
cardiac hypertrophy.8,9 Arguably, CaN’s most well known target is the nuclear factor of
activated T-cells (NFAT) family of transcription factors.4 CaN dephosphorylation of
NFAT reveals a cryptic nuclear localization signal that allows it to move to the nucleus
and initiate a gene program for the activation of T-cells. Because of this immune system
involvement CaN is the target of immunosuppressant drugs.5 Despite its physiological
importance, CaN regulation at the molecular level is still poorly understood but differs
significantly from the CaM activated kinases.
CaN is a heterodimer composed of an A-chain and a B-chain. The ~60-kDa A-chain
houses the catalytic domain, B-chain binding helix, regulatory domain (RD), an
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autoinhibitory domain (AID), and a C-terminal tail (CT).55 The CaM binding region
(CaMBR) is a 24 residue stretch within the regulatory domain (Figure 5.2). The 19-kDa
B-chain is structurally homologous to CaM and binds four calcium ions.57 There are three
dominant CaN isoforms: the neuron specific αCaN, ubiquitous βCaN, and the testes
specific γCaN.58 Here, we discuss αCaN, and further use of CaN will refer to αCaN.
Similar to the CaM activated kinases, CaN has an AID that blocks the catalytic site until
calcium-loaded CaM binds.58 However, unlike the kinases, CaN’s CaM binding region is
N-terminal to the AID and separated from it by 52 residues (Figure 5.1). CaN’s CaMBR
is located in the regulatory domain (RD) of CaN (Figure 5.2). Trypsin digests and other
hydrolysis experiments by Manalan and Klee, and Yang and Klee, respectively,
demonstrated that the RD is readily hydrolyzed, showing that it is flexible and accessible
in nature.58,71 In the structure of full length CaN the electron density for the RD and Cterminal tail (CT) are missing suggesting that these regions are highly mobile.52
Additionally, Romero and Dunker noted that the sequence of the RD gave it the potential
to be disordered.72 The trypsin digests performed by Manalan and Klee also suggested
that the RD of CaN undergoes a large conformational change upon CaM binding as the
highly unprotected RD becomes protected from trypsin digest when CaN is preincubated
with CaM.71 Surprisingly, this potentially disordered RD is 95 residues long, whereas the
CaM binding site is ~24 residues in length, suggesting that CaM binding induces
conformational changes outside of the CaMBR.
Work by Rumi-Masante et al. showed by H/D exchange mass spectrometry and circular
dichroism spectroscopy that a fragment corresponding to CaN’s RD, AID, and CT (RDAID-CT) is disordered in the absence of CaM, though the AID is well-ordered in fulllength, inactive CaN.73 The RD portion of this fragment contains the CaM binding region
and the 52 residues that separate it from the AID. Canonically, CaM’s two lobes wrap
around its target site and induce α-helix in that sequence. How then does CaM activate
CaN with its CaMBR and AID 52 residues apart and with those 52 residues being
disordered?
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Rumi-Masante et al. also showed that upon CaM binding, ~50 residues within the RD
become protected from H/D exchange and that the RD gains approximately fifty residues
of α-helicity.73 About half of these residues reside in the CaMBR while the remainder are
C-terminal to the CaMBR, residing between it and the AID (Figure 5.2b). The high
protection and α-helicity of the CaMBR when CaM is bound is expected given the very
tight binding between CaM and CaN (KD ~1pM) and the manner in which CaM typically
binds its targets.44 The protection and helicity in the region between the CaMBR and
AID, suggested by RD protection in Manalan and Klee’s CaN/CaM trypsin digests and
confirmed by Rumi-Masante et al, suggests a larger scale structuring than just the
sequence CaM directly binds.71,73
Examination of the protected area between the CaMBR and AID reveals that residues 441
to 459 could form an amphipathic α-helix (Figure 5.2c). It is unlikely that a helix in this
region would be an extension of the helix formed at the CaMBR upon CaM binding as
the region between the CaMBR and this proposed helix is populated with glycines and
prolines, residues known to be unfavorable in α-helices (Figure 5.2b).114 An amphipathic
helix in this region would imply the need for the hydrophobic face of the helix to interact
with another hydrophobic region, however we know from Rumi-Masante et. al. that CaM
bound RD-AID-CT does not interact with the remainder of CaN and that the only regions
in the RD-AID-CT to gain significant secondary structure upon CaM binding is the
CaMBR and part of the region between it and the AID.73 Therefore, we hypothesize that
an amphipathic helix in the region between the CaMBR and AID would interact with the
surface of the remainder of the RD:CaM complex when CaM is bound to the CaMBR of
CaN. The end of this proposed helix is seven residues from the beginning of the AID. If it
forms and folds back upon RD:CaM when CaM binds the RD, this could provide the
necessary energy to remove the AID from the catalytic site. We will refer to this possible
helix as the distal helix. In this work, we explore the nature and importance of the
structure and function of this putative distal helix in the RD of CaN.
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Results
RD:CaM secondary structure is similar to that of the RD-AID-CT:CaM
To investigate CaM induced structure and a possible distal helix in the region C-terminal
to the CaMBR we created a construct consisting of only the RD of CaN (Figure 5.2b). It
was shown by Rumi-Masante et. al. via circular dichroism (CD) spectroscopy and H/D
exchange mass spectrometry (HXMS) that there was no detectable gain of structure in the
AID or CT upon CaM binding to the RD-AID-CT fragment.73 To analyze the secondary
structure of the RD we obtained CD spectra of the RD alone. The spectrum is consistent
with that of an unstructured polypeptide chain (Figure 5. 3a).
An equimolar mixture of CaM and a 24-residue peptide corresponding to the CaMBR of
CaN (pCaN) yields a spectrum with increased α-helix as compared to CaM alone, as is
evident from the more negative minima of CaM:pCaN at 208nm and 222nm, indicators
of α-helix (Figure 5.3a). This increase in helicity is expected for CaM binding and
inducing helix in its target. However, an equimolar mixture of CaM and the RD
demonstrates that the RD:CaM complex has greater helical content than the pCaN:CaM
complex (Figure 5.3a). These data are similar to that seen by Rumi-Masante et.al. for
CaM, pCaN:CaM, RD-AID-CT, and RD-AID-CT:CaM.73
CaM induced RD structure is less stable than pCaN:CaM
Thermal melts of pCaN:CaM and RD:CaM from 10°C to 95°C were obtained monitoring
CD at 222nm, the wavelength associated with minima in CD spectra caused by α-helices.
The pCaN:CaM melt reveals no melting transitions, indicating that the pCaN:CaM
complex is stable to at least 95°C. The melt of RD:CaM, however, shows a melting
transition with Tm~40°C (Figure 5.3b). The major sequence difference between
pCaN:CaM and RD:CaM lies with the addition of the region C-terminal to the CaMBR
(Figure 5.2b), thus the melting transition seen in RD:CaM is consistent with the melting
of a helix in this region.
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Disruption of the hydrophobic face of the putative distal helix alters CaM induced
secondary structure
The hydrophobic face of the putative distal helix is composed of a leucine, isoleucine,
and three alanines (Figure 5.2c). We created three RD mutants, RD-A447E, RD-A451E,
and RD-A454E, that would disrupt the hydrophobic face but not necessarily prevent the
formation of a helix as glutamates are charged but have high helical propensities.114 The
CD spectra of these mutants demonstrate that they are unstructured polypeptide chains
similar to wild-type RD (Figure 5.4a).
In contrast, addition of equimolar CaM to the RD mutants yields CD spectra that have
helical content more similar to that of pCaN:CaM, not RD:CaM (Figure 5.4b).

The

similarity of the RD mutant:CaM spectra to the pCaN:CaM spectrum indicates that
secondary structure in the region between C-terminal to the CaMBR has been disrupted
by the alanine to glutamate mutations. However, the RD mutant:CaM spectra have
slightly stronger 222nm minima than pCaN:CaM, with RD-A454E being the strongest,
suggesting that they may have some residual distal helix.
Disruption of the hydrophobic face of the putative distal helix alters CaM induced
helix stability
Thermal melts of the RD mutants RD-A447E, RD-A451E, and RD-A454E, with CaM
were obtained, monitoring the CD at 222nm from 10°C to 95°C as for pCaN:CaM and
RD:CaM above. Consistent with the CD spectra (Figure 5.4b), the RD mutants with CaM
have more strongly negative signals than pCaN:CaM at the beginning of the melt, with
RD-A454E being the strongest (Figure 5.4c). This is indicative of more α-helix in the
mutants with CaM than pCaN:CaM. However, all the mutants have signals approaching
that of pCaN by the end of the melts. Wild-type RD:CaM has a stronger helical signal
than any of the mutants with CaM or pCaN:CaM, demonstrating its increased helicity in
the region C-terminal to the CaMBR. Despite its weakened helical signal as compared to
RD:CaM, RD-A454E:CaM does have a melting transition. The Tm for this melting could
not be obtained due to the absence of a native baseline for the RD-A454E:CaM melt. The
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weaker helical signal of RD-A454E:CaM compared to RD:CaM combined with the
presence of a melting transition suggests that the RD-A454E retains a partial distal helix,
more than that of the other mutants, but the helix is diminished as compared to wild-type
RD.
Disruption of the hydrophobic face of the putative distal helix diminishes CaM
activated CaN activity
To investigate the impact of the disruption of the hydrophobic face of the putative distal
helix on CaN dephosphorylation kinetics we created the same three alanine to glutamate
mutations in full-length CaN as we did in the RD: CaN-A447E, CaN-A451E, and CaNA454E. The CaM induced activity of these mutants, as well as wild-type CaN, was
assessed with a malachite green free phosphate assay using varying concentrations of pRII peptide from cAMP dependent protein kinase regulatory subunit (type II), a well
characterized CaN substrate.81,82 Reactions were performed with 1:3 CaN:CaM or CaN
mutant:CaM. Various divalent cations are known to impact CaN’s activity in different
ways.81 In our assays we include calcium and magnesium. Table 1 gives the kinetic
parameters for CaN and the CaN mutants obtained under the conditions of our assay. This
kinetic analysis of CaN and CaN mutant dephosphorylation activity reveals increased Km
values for the CaN mutants as compared to wild-type CaN (Table 1). The increased Km
values demonstrate that the integrity of the hydrophobic face of this putative helix is both
important for CaN activity and also impacts CaN’s ability to bind substrate.
Discussion
In CaM activated kinases the CaMBR is directly C-terminal to the AID (Figure 5.1).112,113
This proximity allows

CaM to bind, causing the CaMBR to form an α-helix which

removes the AID from the catalytic site, activating the kinase. Despite CaN having both a
CaMBR and AID as the CaM activated kinases do, CaM activation of CaN cannot occur
in the same way as the CaM activated kinases given that the C-terminal end of the
CaMBR is 52 residues N-terminal to the AID and these residues are disordered in the
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absence of CaM (Figure 5.1).

56,71,73

The intervening disordered residues seemingly

prevent the removal of the AID from the active site when CaM binds at CaN’s CaMBR.
Proteolytic digest work by Manalan and Klee and Yang and Klee showing that the RD is
readily degraded by proteases; missing RD and CT electron density in the CaN structure;
and sequence analysis by Romero and Dunker all suggested that the RD is disordered.
52,56,71,72

Additionally, Manalan and Klee’s trypsin digests of CaN preincubated with CaM

showed that the RD became protected when CaM was bound to CaN, suggesting that the
RD undergoes a conformational change upon CaM binding.71 Rumi-Masante, et al
showed that the RD-AID-CT is disordered but gains structure upon CaM binding.73 This
structure includes the expected α-helix in the CaMBR, but it also includes one or more
regions of helical structure somewhere between the end of the CaMBR and the beginning
of the AID.
In this work, we investigated a construct of the RD alone. Our CD spectra for RD and
RD:CaM are comparable to those for RD-AID-CT and RD-AID-CT:CaM done by RumiMasante, et al, confirming that the α-helix gained upon CaM binding is in the RD, not the
AID or CT.73 We also performed thermal melts of pCaN:CaM and RD:CaM. The thermal
melt of pCaN:CaM shows no cooperative melting transition as pCaN:CaM is extremely
stable (KD for CaN:CaM is ~1pM) and does not melt within the 10°C to 95°C range of
our thermal melts.44 Therefore, the melting transition seen in the RD:CaM thermal melt
must come from melting of helical structure in the RD outside of the CaMBR. Thus,
CaM induced helical content is both in the CaMBR and the remainder of the RD (Figure
5.3).
Upon examination of the sequence in the region of the RD C-terminal to the CaMBR,
identified by Rumi-Masante et al as the region besides the CaMBR that gains structure
upon CaM binding, we identified a portion that plots as an amphipathic helix on a helical
wheel projection (Figure 5.2c). 73 From this we proposed that an amphipathic helix in this
region forms by folding its hydrophobic face onto the surface of the rest of the RD:CaM
complex when CaM is bound to the CaMBR of CaN. We refer to this helix as the distal
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helix. Rumi-Masante et al showed that CaM bound RD-AID-CT does not interact with
CaN’s catalytic domain, B-chain binding helix, or B-chain, making the remainder of the
RD:CaM complex the only other portion of CaN that the distal helix could interact with.
Interaction of the distal helix with the remainder of the RD:CaM complex would create a
hairpin-like chain reversal that could compensate for the 52 residues between the CaMBR
and AID allowing for the removal of the AID from the catalytic site, activating CaN. This
helix would not be an extension of the CaMBR helix as the region between the CaMBR
and this helix contains multiple glycines and prolines, residues known to be unfavorable
in α-helices.
To test for the presence of the distal helix we created three RD mutants: RD-A447E, RDA451E, and RD-A454E (Figure 5.2). The alanine to glutamate mutations would disrupt
the hydrophobic face of the helix but not necessarily prevent the formation of a helix as
glutamates are charged but have high helical propensities.114 CD spectra of these mutants
were comparable to wild-type RD showing that they are disordered, but upon CaM
binding the helical content gained is similar to that of pCaN:CaM, not RD:CaM (Figure
5.4a,b). This indicates that the mutations have caused a reduction in CaM-induced helical
content.
Thermal melts of the RD mutants with CaM were similar to the thermal melt of
pCaN:CaM, demonstrating that the lost helical content is in the RD, but outside of the
CaMBR (Figure 5.4c). Though the CD spectra and melts are closer to pCaN:CaM than
RD:CaM, the RD-A454E:CaM and RD-A447E:CaM complexes shows more residual
helical content than RD-A451E:CaM. RD-A454E:CaM even has a visible melting
transition, though a Tm could not be determined. As A451 is central to the distal helix,
and A447 and A454 would be nearer the N- and C-terminal limits of the helix, mutation
of the central alanine (A451) may disrupt the entire helix whereas mutation of the
alanines closer to the termini (A447 and A454) may still allow for partial formation of the
distal helix. We also note that thermal melting of the RD showed that the distal helix’s Tm
is ~40°C, very near physiological body temperature of 37°C, suggesting that it is not very
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stable. Given this, the reduced helical content of the hydrophobic face mutants, and the
absence of this helix when CaM is not bound to CaN suggests that the helix requires that
its hydrophobic face interact with the remainder of the RD:CaM complex in order for it
to form.
To investigate the importance of the distal helix in CaN dephosphorylation activity, we
created the same mutations in full-length CaN as we did in the RD: CaN-A447E, CaNA451E, and CaN-A454E. Performing malachite green free phosphate assays on CaM
activated wild-type CaN and these mutants revealed increased Kms in the mutant CaNs as
compared to wild-type (Table 1). The increased Kms demonstrate a reduced affinity for
substrate in the mutant CaNs. This alteration in kinetic parameters shows that the proper
formation of the distal helix is important for CaN dephosphorylation, but it is of note that
the mutants diminish CaN activity, they do not abolish it. The increased mutant CaN Kms
suggest that the AID can still bind the active site in these mutants, even in the presence of
CaM. However, the residual activity in these mutants suggests that in the CaN mutants
with CaM the AID binding in the active site is not as tight as it is in wild-type CaN
without CaM, likely due to residual distal helix in the mutants.
Based on our alanine mutation studies we have shown that the distal helix is comprised of
at least eight residues if A447 and A454 are considered to be the bounds of the helix.
However, trypsin digest work by Rumi-Masante et al shows that both K441 and K459 are
protected from digestion, suggesting that the distal helix may extend from residue 441 to
459, beyond the alanine limits (Figure 5.2b).73 This gives an ~19 residue helix, which is
consistent with the helical gain seen in the region between the CaMBR and AID by
Rumi-Masante et al. This is also consistent with our helical wheel projection (Figure
5.2c).
We have shown that disruption of the hydrophobic face of the putative distal helix
diminishes the helical content in this region and reduces CaN’s affinity for substrate.
Residual CaN activity when the hydrophobic face of the distal helix is disrupted may be
due to residual helicity of the distal helix. In light of the importance of the distal helix for
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CaN activity, we propose the following model for CaN activation by CaM: When CaM
binds to the CaMBR in the RD of CaN a stretch of residues N-terminal to the AID forms
an amphipathic α-helix, which we have termed the distal helix. The hydrophobic face of
the distal helix must interact with another hydrophobic region on the remainder of the
RD:CaM complex to form. This interaction creates a hairpin-like chain reversal in the RD
that compensates for the 52 residues between the CaMBR and AID, and allows the AID
to be removed from CaN’s catalytic site when CaM binds, activating CaN.
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Figure 5.1: Domain ordering of CaM activated kinases compared to the domain ordering
of CaN
In CaM activated kinases, the AID is just N-terminal to the CaM binding domain,
allowing for easy removal of the AID from the kinase active site upon CaM binding. In
CaN, the AID is 52 residues C-terminal to the end of CaM binding domain suggesting a
different mode of CaM activation in CaN from the kinases.

Copyright © Victoria Beth Dunlap
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Figure 5.2: Calcineurin domain structure and regulatory domain schematics
a. Structure of CaN with domains highlighted. Catalytic domain: purple; CnB binding
helix: blue; Regulatory domain (RD): green, drawn, electron density is missing from
crystal structure; CaM binding region: orange rectangle, drawn, electron density is
missing from crystal structure;Autoinhibitory domain (AID): red; C-terminal tail (CT):
light gray, drawn, electron density is missing from crystal structure; Calcineurin B (CnB):
dark gray. PDBID:1AUI.52 b. Sequence of RD construct with distal helical region
highlighted by the blue region and the mutated alanine residues underlined. RD: green,
CaMBR: orange, portion of AID: red, extraneous sequence: gray. Extraneous sequence
was added for protein expression and purification purposes. c. Helical wheel projection of
the distal helix. The alanine to glutamate mutations made on the hydrophobic face are
indicated. N and C mark the N-terminal and C-terminal residues of the putative helix,
respectively.
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Figure 5.3: CD spectra and melts of RD, CaM, pCaN, and complexes
a. Far UV CD spectra collected at 20°C for RD, CaM, pCaN complexed with CaM, and
RD complexed with CaM. b. Thermal melts following CD signal at 222nm from 10°C to
95°C for pCaN complexed with CaM and RD complexed with CaM.
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Figure 5.4: CD spectra and melts of RD mutants and RD mutant:CaM complexes
Far UV CD spectra collected at 20°C

for a. RD, RD-A447E, RD-A451E, and RD-

A454E as well as b. the following, each complexed with CaM: pCaN, RD, RD-A447E,
RD-A451E, RD-A454E. c. Thermal melts following CD signal at 222nm from 10°C to
95°C for each of the following complexed with CaM: pCaN, RD, RD-A447E, RDA451E, RD-A454E.
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Table 5.1: Kinetic parameters of CaN and CaN distal helix mutants for
dephosphorylation of p-RII peptide

Km (µM)

Vmax (umol min-1 mg-1)

CaN

464 ± 60

12.0 ± 0.9

CaN-A447E

478 ± 114

8.7 ± 1.2

CaN-A451E

899 ± 213

9.7 ± 1.5

CaN-A454E

589 ± 101

11.1 ± 1.1
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Chapter 6: Conclusions and future directions, a model for calcium/CaM
regulation of CaN
Calcineurin (CaN) signaling is vitally important for the fetal development of numerous
tissues, necessary for T-cell activation, and important in learning and memory. Not only is
CaN important in human physiology, but it is highly conserved and necessary for survival
from yeast to humans.4 CaN signaling is very well studied, largely due to CaN’s role in
the activation of the NFAT (nuclear factor of activated T-cells) family of transcription
factors by dephosphorylation. Because NFAT signaling in T-cells leads to activation of Tcells, CaN has become the target of immunosupressant drugs.4,5
CaN is a heterodimer composed of a 57-61kDa A chain (CnA) and a 19kDa B chain
(CnB). CnA is composed of the catalytic domain, CnB binding helix (CnBBH),
regulatory domain (RD), autoinhibitory domain (AID), and C-terminal tail (CT) (Figure
1.3).55 It is known that at low calcium concentrations the AID resides in the catalytic site
of CnA, keeping the enzyme inactive. When calcium levels rise, calcium loaded CaM
binds to the CaM binding region (CaMBR) located in the regulatory domain of CnA.
CaM binding releases the AID from the catalytic site, activating CaN.56 CnB is a calcium
binding EF hand protein that is structurally homologous to CaM and is constitutively
bound to CnA, regardless of calcium concentrations.57
Despite being important and highly studied, there is much we do not know about the
protein CaN. The efforts in this body of work have focused on furthering our
understanding of the physical aspects of calmodulin (CaM) regulation of CaN. The work
of many who have come before us has shown that the isolated regulatory domain is
disordered in the absence of CaM but undergoes a conformational change upon CaM
binding that induces α-helical structure in the RD and, in full-length CaN, removes the
AID from CaN’s catalytic site to activate the enzyme.52,71-73,115 This knowledge brings
with it more questions.
A disordered protein or protein region is not devoid of all structure but exists as a
conformational ensemble that can be anywhere from loosely packed coils to compact and
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globular. To describe the RD of CaN as disordered only puts it into this wide spectrum.
Thus, we sought to discover the nature of the disorder in the RD and the change in that
disorder upon CaM binding (Chapter 3). We examined this by investigating the rotational
and translational diffusions of the RD ± CaM using fluorescence anisotropy and
fluorescence correlation spectroscopy, respectively. Our studies have shown that, given
its low net charge per residue, the RD likely exists as this compact, globular ensemble,
but CD, anisotropy, and FCS experiments demonstrate that the RD undergoes further
collapse upon CaM binding, gaining persistent α-helical secondary structure in which the
RD:CaM complex has a similar hydrodynamic radius to that of the RD or CaM alone.
However, a comparison of the anisotropy of RD with a label on the C-terminus vs the Nterminus, with CaM, suggested that C-terminus of the RD remains at least somewhat
flexible and disordered upon CaM binding. Given what we later learned about the
existence of the distal helix (Chapter 5) C-terminal to the CaMBR, that it is important for
efficient CaN activity but only partially stable with a Tm of ~40°C, we believe that the
apparent partial disorder remaining at the C-terminus of the RD upon CaM binding is
likely the result of transient folding and unfolding of this helix. However, we note that the
Tm of the helix in vivo may be higher due to the crowding conditions found in cells.
It was also noted that there remained uncertainty concerning the stoichiometry of the
CaN:CaM complex. Ye et al. and Majava et al. have published crystal structures that
demonstrate a 2:2 complex of a peptide corresponding to the CaMBR of CaN (pCaN) and
CaM.70,74,75 However, solution work by these groups as well as extensive hydrodynamic
and NMR studies by O’Donnell et al. suggested the dominant stoichiometry in solution is
1:1, with only a minor fraction existing as a 2:2 complex when the 2:2 complex was seen
at all.44,70,74,75
Without a confirmed knowledge of the stoichiometry of the CaM:CaN complex, any
attempt to understand the mechanism by which CaM activates CaN would be incomplete.
We attempted to reconcile the 2:2 solid-state complex and the 1:1 solution complex by
using x-ray crystallography to solve the structure of the CaM:pCaN complex and
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analytical size-exclusion chromatography (SEC) on CaM:RDC, with RDC being a
construct of the C-terminal portion of the RD from the beginning of the CaM binding
region to the beginning of the AID. Both the SEC studies and our crystal structure
demonstrated a 1:1 complex, with no observable 2:2 complex present. The 1:1 complex
of one CaM molecule wrapping around one pCaN peptide is consistent with the NMR
work and extensive hydrodynamic work done by O’Donnell et al. as well as previously
published structures of CaM binding to other basic, amphipathic α-helical peptides of the
same CaM binding target class as pCaN.44,110 Our 1:1 CaM:pCaN crystal structure and
SEC data for the CaM:RDC complex strongly suggest that a single CaM molecule is
responsible for binding to and activating CaN.
We know now that CaM binds to a disordered RD with 1:1 stoichiometry, wraps around
the CaMBR, and causes a conformational ordering in the RD that removes the AID from
CaN’s catalytic site, activating the enzyme. So, how does the ordering that CaM induces
in the RD remove the AID from CaN’s active site? There are 52 residues from the end of
the CaMBR to the beginning of the AID. If CaM bound the RD and only induced α-helix
in the CaMBR, 52 residues would be plenty of disordered sequence space to allow the
AID to remain bound in the active site. However, Rumi-Masante et al. showed that ~25
residues in this region gain α-helical structure upon CaM binding.73
Examination of the protected area between the CaMBR and AID reveals that residues 441
to 459 could form an amphipathic α-helix (Chapter 5, Figure 5.2). It would be unlikely
for this to be an extension of the CaMBR helix as the intervening sequence is populated
with glycines and prolines which are unfavorable in helices.114 An amphipathic helix in
this region would imply the need for the hydrophobic face of the helix to interact with
another hydrophobic region, and we hypothesized an amphipathic helix in the region
between the CaMBR and AID would interact with the surface of the remainder of the
RD:CaM complex when CaM is bound to the CaMBR of CaN. The end of this proposed
helix is seven residues from the beginning of the AID. If it were to form and fold back
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onto the surface of CaM in a hairpin-like chain reversal, it could provide the force
necessary to remove the AID from the active site.
We explored the possibility of this helix and its function in CaN activity by creating
mutations in the isolated RD and full-length CaN that would disrupt the hydrophobic face
of the helix. We obtained CD spectra and melts of the WT-RD and mutants ± CaM, as
well as performed CaN phosphatase assays on WT-CaN and mutants in the presence of
CaM. Our work demonstrated that disruption of the hydrophobic face of what we termed
the distal helix diminishes the helical content in this region and reduces CaN’s affinity for
substrate. Residual CaN activity when the hydrophobic face of the distal helix is
disrupted may be due to residual helicity of the distal helix.
Our work has demonstrated that CaM binds to a disordered RD with 1:1 stoichiometry
and causes a compaction of the RD that includes the formation of the distal helix, an
element important for efficient CaN activity. From this the question arises: Why does the
distal helix exist? In lower eukaryotes, such as drosophila and yeast species, the distal
helix sequence is absent (Figure 6.1). It seems that the absence of the sequence for the
distal helix would allow for the direct removal of the AID from CaN’s active site without
the need for the hairpin-like chain reversal that the distal helix causes. CaM binding to
and inducing α-helix in the CaMBR may alone provide the steric force necessary to
remove the AID in the absence of the distal helix. Drosophila CaN is very similar to
human CaN both in sequence and length, but in drosophila the helical sequence is
missing, possibly allowing for direct removal of the AID. Many yeast species also have a
deletion of the distal helix sequence, however they also have an insertion in the RD, Nterminal to the CaMBR (Figure 6.1). In Aspergillus fumigatus the insertion has several
serine-proline motifs, the phosphorylation of which is crucial for appropriate CaN
signaling (Juvvadi, P.R., et al., in revision).
It seems that the variations in the RD amongst species are added levels of CaN
regulation. In Aspergillus fumigatus phosphorylation in the RD regulates CaN signaling,
and in drosophila the distal helix is missing, possibly allowing for quicker, more efficient
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activation of CaN. So, if these variations are regulatory elements, what is the regulatory
function of the distal helix in humans? The answer may lie in the calcium binding
abilities of CnB.
CnB is the calcium binding subunit of CaN. It is structurally homologous to CaN with
four calcium binding EF-hands. CnB binds CnA in an antiparallel manner where the Cterminal lobe of CnB binds to the N-terminal end of the CnB binding helix (CnBBH) and
forms an interface with the catalytic domain of CnA. The N-terminal lobe of CnB binds
to the C-terminal end of the CnBBH. The C-terminal lobe EF-hands are the high affinity
calcium binding sites with KD ~70nM.60 The N-terminal lobe calcium affinity is ~20µM.
60 At

low calcium conditions comparable to resting cellular concentrations, the C-terminal

lobe of CnB is calcium loaded and bound to CnA. However, the N-terminal lobe of CnB
would be devoid of calcium and partial proteolytic digests suggest that, in the absence of
calcium binding, the N-terminal lobe does not bind the CnBBH.56 Furthermore, these
partial proteolytic digests also show that the RD in CaN is protected from digest in the
absence of calcium but is rapidly degraded when calcium is present.56,71 This suggests
that a portion of the RD folds onto CnB or the CnBBH in the absence of calcium, and
calcium binding to the N-terminal lobe of CnB causes it to bind the CnBBH, releasing the
RD.
Brian Perrino, who is now at the University of Nevada, Reno, created a construct
corresponding to the RD from the end of the CaMBR to the end of the C-terminal tale,
encompassing the distal helix and AID, AI420-511.116 When assayed with constitutively
active CaN (CaN1-420, missing the distal helix and AID-CT) this construct is an ~fivefold better inhibitor of CaN than the AID alone.116 Full activation of CaN requires both
calcium binding to CnB and calcium-loaded CaM binding to the RD. Calcium binding to
the CnB results in a lowered Km while CaM binding increases the Vmax. Addition of
calcium to CaN (in the absence of CaM) lowers the Km ~three-fold.64 Our hypothesis is
that a portion of the RD including the distal helix interacts with CnB/CnBBH in the
absence of calcium and is released upon calcium binding. The interaction of the distal
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helix region with CnB/CnBBH likely blocks substrate access to the LxVP docking site
that is located at the CnB/CnA interface. Release of the distal helix from CnB/CnBBH
would decrease the Km of CaN (increasing CaN’s substrate affinity) by exposing the
LxVP docking site, allowing substrate to bind. We do not discount the role of CnB in
propagating a conformational change to the catalytic domain upon calcium binding. It is
likely that this occurs in addition to the changes in the RD, as lower eukaryotes without
the distal helix still require CnB for CaN function. Thus, it seems the distal helix may
play a calcium sensitive regulatory role in allowing substrate binding to the LxVP
docking site.
However, this does not fully explain the role of the distal helix in CaN regulation as we
have seen that drosophila are missing the distal helix and have no RD insertion that could
compensate for the missing distal helix. Why does drosophila not need the regulation
provided by a distal helix, as seen in humans, or an N-terminal RD insertion, as seen in
yeast? The answer is not readily apparent, but could be addressed by examining the
activity of wild-type drosophila CaN as well as drosophila CaN with a distal helix
insertion or an N-terminal RD insertion, both in vitro and in cellular environments. We
also note that the LxVP docking site that we believe the distal helix blocks under low
calcium conditions is not the only substrate docking site. The PxIxIT motif present in
NFAT substrates as well others docks on CnA, opposite from the LxVP docking site
(Chapter 1, Figure 1.2). LxVP docking seems to be important for substrate recognition,
but the use of the PxIxIT docking site may allow for some substrates to bind CaN even in
low calcium conditions, giving them ready access to the LxVP docking site when it
becomes available.21
Our current model for calcium/CaM activation of CaN is: at resting cellular calcium
levels the N-terminal lobe of CnB is devoid of calcium and not bound to the CnBBH.
This allows the distal helix region of the RD to interact with CnB/CnBBH, occluding the
LxVP substrate docking site. When calcium levels increase, the RD is released from its
interaction with CnB/CnBBH by the N-terminal lobe of CnB binding calcium and then
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the CnBBH. Release of the RD from CnB/CnBBH exposes the LxVP site, allowing for
substrate docking at this site. Calcium-loaded CaM then binds the now disordered RD,
causing formation of the distal helix which folds upon CaM in a hairpin-like chain
reversal. The formation and chain reversal of the distal helix removes the AID from
CaN’s catalytic site, causing the full activation of CaN (Figure 6.2).
Calcium binds to CaM with KDs of ~0.2µM and ~2µM at the C-terminal and N-terminal
lobes, respectively.117-119 The N-terminal lobe of CnB has a KD of calcium binding of
~20µM.60 Thus, even the low affinity calcium binding N-terminal lobe of CaM has a 10fold higher calcium affinity than the N-terminal lobe of CnB. This suggests that when the
CnB N-terminal lobe binds calcium and then the CnBBH, releasing the RD, CaM is
already calcium loaded and ready to bind the RD as soon as it is available. While
disordered proteins and regions have been shown to exist, and it has been proven that the
disorder is often necessary for a protein’s function, it remains a mystery as to how
disordered proteins and regions survive a cellular environment that is designed to degrade
and dispose of misfolded and unfolded proteins. The system of RD disorder and CaM
binding may provide insight. If CaM is calcium loaded and ready to bind the RD as soon
as it is released from the CnB/CnBBH, then the disorder of the RD is very transient. The
disorder of the RD is important to allow CaM binding, but the disorder exists only for a
short time before CaM binding, especially given that the KD of calcium loaded CaM
binding to CaN is ~1pM.44 Before calcium binding to the CnB, the RD is protected by
interaction with the CnB/CnBBH, and as soon as it is released CaM binds, and it is
protected by interaction with CaM. Thus, transient disorder may be one mechanism by
which the necessary disorder of some proteins is controlled in cellular environments.
Our new knowledge of the disordered nature of the isolated RD and the formation and
possible regulatory function of the distal helix has significantly contributed to our
understanding of CaM activation of CaN, but it also raises new questions. At low calcium
levels, we hypothesize the distal helix region of the RD binds to CnB/CnBBH, occluding
the LxVP substrate binding site. We can investigate this possibility by obtaining a
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fluorescently labeled peptide corresponding to the distal helix region of the RD and
measure the fluorescence anisotropy of the peptide with and without CaN373, a construct
that includes CnA up to the end of the CnBBH and CnB. This must be done in the
absence of calcium. If the peptide binds CaN373, it may be possible to obtain an
anisotropy binding curve to determine the affinity of binding. We can mutate residues in
the CnBBH and LxVP docking site and measure the anisotropy of binding of the distal
helix peptide to these mutants for comparison to the binding of peptide to CaN373.
Additionally, a fluorescently labeled peptide of a substrate LxVP motif could be obtained
and its anisotropy measured with/without CaN373 and the distal helix peptide. If the
distal helix peptide blocks the LxVP docking site, the LxVP motif peptide will not be
able to bind CaN373 in its presence without calcium. These experiments will demonstrate
where the distal helix peptide binds and if it occludes the LxVP binding site.
Proteolytic studies suggest that calcium binding in the N-terminal lobe of CnB causes it
to bind the CnBBH and release the RD.56,71 Assuming the fluorescent studies above
reveal distal helix sequence binding to CaN373, the release of the RD can be tested by
measuring the anisotropy of the same peptide, testing its binding to CaN373 both in the
absence and presence of calcium. Introduction of calcium into the system should cause
the release of the peptide, decreasing its anisotropy. Also, measurement of the binding of
the LxVP motif peptide to CaN373 via anisotropy measurements with/without calcium
and the distal helix peptide will reveal if release of the distal helix exposes the LxVP
motif. Additionally, we can use site-directed mutagenesis to disrupt the calcium binding
sites in the N-terminal lobe of CnB. This disruption should prevent CnB N-terminal lobe
binding to the CnBBH even under high-calcium conditions. Using this CnB mutant in
CaN373, we can determine if disrupting calcium binding changes RD binding to the
CnBBH and if disrupting calcium binding changes LxVP motif binding.
We see that, in drosophila, the region of the RD that contains the distal helix is simply
missing, yet CaN signaling obviously still works in drosophila. Thus, we can make the
distal helix deletion in human CaN, as it is in drosophila, and examine the affect that it
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has on CaN inhibition and activity at both high and low levels. Anisotropy measurements
with this deletion construct and the fluorescent LxVP motif peptide ± calcium would
confirm whether or not the distal helix sequence blocks the LxVP docking site under low
calcium conditions. Also, we can further investigate the impact of the distal helix on CaN
activity by testing the activity of this distal helix deletion mutant with and without
calcium/CaM.
If the distal helix region interacts with CnB/CnBBH under low calcium conditions, it
would become disordered when it is released upon CnB N-terminal lobe calcium binding.
This is suggested by previous proteolytic studies, CaN crystal structure, previous CD
spectroscopy, and our own CD and anisotropy studies.52,56,71-73 However, these studies are
done in vitro and the solutions used are very dilute compared to the crowded conditions
of the cell. It is possible that the crowding of a cellular environment causes a partial
ordering of the RD that still allows CaM binding. As a proxy for crowding, the propensity
for structure of the RD in the absence of CaM can be examined by CD spectroscopy and
fluorescence anisotropy experiments with the RD in increasing concentrations of
osmolytes such as trimethylamine N-oxide (TMAO) and 2,2,2-trifluorethanol (TFE). TFE
is known to induce α-helix in peptide chains with a propensity for helix whereas TMAO
can induce general structure. The low net charge per residue of the RD suggests that,
while it is disordered, it is relatively compact and globular in shape. If the RD’s
conformational ensemble is restricted in this way, addition of chaotropes, or denaturants,
such as guanidine, urea, and thiourea could disrupt the compact, globular ensemble,
affecting the CD spectra and anisotropies of the RD. Both the osmolytes and denaturants
can be used as tools to further investigate the disordered state of the RD.
Finally, after an increase in calcium causes the N-terminal lobe of CnB to bind calcium
and then bind to the CnBBH, releasing the RD; CaM is then able to bind the RD, induce
formation of the distal helix, and removal of the AID from the catalytic site, activating
CaN. The distal helix is amphipathic which necessitates a hydrophobic surface for its
hydrophobic face to interact with. This surface is likely on the surface of CaM, allowing
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the distal helix to undergo its hairpin-like chain reversal that would remove the AID from
the active site. To better understand this interaction, we must learn where on CaM the
distal helix binds. We can attempt to grow crystals of CaM with the RDC, as this is the
smallest piece of the RD that still includes the CaMBR and distal helix. If diffraction
quality crystals are obtained, we can use our CaM:pCaN crystal structure for molecular
replacement to help solve the structure and determine the distal helix placement.
However, as we have observed through anisotropy measurements and CD melts, the
distal helix is only partially stable. This may make it mobile in crystal form and its
placement on CaM unobtainable. If this is the case, we could employ NMR spectroscopy
to determine the structure of the RDc:CaM complex. The complex at 27.1kDa is a
tractable size for NMR.
As we have seen CaM binds to a disordered RD with 1:1 stoichiometry and causes a
compaction of the RD that includes the formation of the distal helix, an element
important for efficient CaN activity. This points to further investigation of the RD of CaN
when calcium levels are low to determine if the distal helix region occludes the LxVP
binding site; when calcium levels are increased but there is no CaM to observe the nature
of the disorder in the RD with osmolytes or denaturants; and when both calcium and
CaM are present to determine where on CaM the hydrophobic face of the distal helix
interacts. Our studies and literature thus far have led us to this model: at resting cellular
calcium levels the N-terminal lobe is devoid of calcium and not bound to the CnBBH.
This allows the distal helix region of the RD to interact with CnB/CnBBH, occluding the
LxVP substrate docking site. When calcium levels increase, the RD is released from its
interaction with CnB/CnBBH by the N-terminal lobe of CnB binding calcium and then
the CnBBH. Release of the RD from CnB/CnBBH exposes the LxVP site, allowing for
substrate docking at this site. Calcium-loaded CaM then binds the now disordered RD,
causing formation of the distal helix which folds upon CaM in a hairpin-like chain
reversal. The formation and chain reversal of the distal helix removes the AID from
CaN’s catalytic site, causing the full activation of CaN (Figure 6.2). Our work on
calmodulin activation of calcineurin has lead us to a better understanding of the
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molecular mechanism by which this activation occurs. It also leads us to new questions,
the study of which will give us a better understanding of how CaN substrate recognition
is regulated. As our understanding of CaN regulation increases we are better positioned to
investigate and control CaN in human health, especially with respect to the use of
immunosupressant drugs for organ and tissue transplant patients.

Copyright © Victoria Beth Dunlap
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Figure 6.1: Sequence alignment of the RD
Sequence alignment of the RD from S. cerevisiae, S. pombe, D. melanogaster, and H.
sapien is shown. The distal helix sequence is underlined in human. Of note is the
insertion in S. cerevisiae and S. pombe in the region N-terminal to the CaM binding
domain and the deletion of the distal helix in all non-human species shown.
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Figure 6.2: Model for the activation of CaN by calcium/CaM
From left to right: at low calcium levels, the CnB N-terminal lobe is unbound by calcium
and does not bind the CnBBH, allowing the RD to interact with this region. An increase
in calcium causes the CnB N-terminal lobe to bind calcium and then the CnBBH,
releasing the regulatory domain. The disordered domain is now available for calciumloaded CaM to bind. CaM binding induces formation of a distal helix that allows for
removal of the AID from CaN’s catalytic site, activating the enzyme.
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